<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2510234393
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        XULTOPHY 100 U/ml + 3.6 mg/ml Solution for  Injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        INSULIN DEGLUDEC,LIRAGLUTIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100,3.6
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        821.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVO NORDISK" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10AE56
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Xultophy<sup>&reg;</sup> is used for</strong></p><p>Xultophy<sup>&reg;</sup> is used to improve blood glucose (sugar) levels in adult patients with type 2 diabetes mellitus. You have diabetes because your body:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; does not make enough insulin to control the level of sugar in your blood or</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is not able to use the insulin properly.</p><p>&nbsp;</p><p><strong>How Xultophy<sup>&reg;</sup> works </strong></p><p>Xultophy<sup>&reg;</sup> contains two active substances that help your body control your blood sugar:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; insulin degludec &ndash; a long-acting basal insulin which lowers your blood sugar levels.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liraglutide &ndash; a &lsquo;GLP-1 analogue&rsquo; that helps your body make more insulin during meals and lowers the amount of sugar made by your body.</p><p>&nbsp;</p><p><strong>Xultophy<sup>&reg;</sup> and oral medicines for diabetes</strong></p><p>Xultophy<sup>&reg;</sup> is used with oral medicines for diabetes (such as metformin, pioglitazone and sulfonylurea medicines). It is prescribed when these medicines (used alone or with GLP-1 treatment or with basal insulin) are not enough to control your blood sugar levels.</p><p>&nbsp;</p><p><strong>If you use GLP-1 treatment</strong></p><p>You should stop your GLP-1 treatment prior to starting on Xultophy<sup>&reg;</sup>.</p><p>&nbsp;</p><p><strong>If you use insulin</strong></p><p>You should stop your insulin treatment prior to starting on Xultophy<sup>&reg;</sup>.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use </strong><strong>Xultophy<sup>&reg;</sup></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-ansi-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_07bdc396-1e2b-4e6d-af67-9b27fe3d0dad \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-ansi-language:
EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to insulin degludec or liraglutide or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-ansi-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_06b8f185-b5fe-43aa-8506-c88acdc3f289 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-ansi-language:
EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Talk to your doctor, pharmacist or nurse before using Xultophy<sup>&reg;</sup>.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are also taking a sulfonylurea (such as glimepiride or glibenclamide), your doctor may tell you to lower your sulfonylurea dose depending on your blood sugar levels.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use Xultophy<sup>&reg;</sup> if you have type 1 diabetes mellitus or if you have &lsquo;ketoacidosis&rsquo; (a condition with a build-up of acid in the blood).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The use of Xultophy<sup>&reg;</sup> is not recommended in patients with inflammatory bowel disease or delayed gastric emptying (diabetic gastroparesis).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you know that you are due to have surgery where you will be under anaesthesia (sleeping), please tell your doctor that you are taking Xultophy<sup>&reg;</sup></p><p>&nbsp;</p><p>&nbsp;</p><p>Be especially aware of the following when using Xultophy<sup>&reg;</sup>:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood sugar (hypoglycaemia) &ndash; if your blood sugar is low, follow the advice in section 4 &lsquo;Low blood sugar (hypoglycaemia)&rsquo;.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood sugar (hyperglycaemia) &ndash; if your blood sugar is high, follow the advice in section 4 &lsquo;High blood sugar (hyperglycaemia)&rsquo;.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ensuring you use the right medicine &ndash; Always check the pen label before each injection to avoid accidentally confusing Xultophy<sup>&reg;</sup> with other products.</p><p>&nbsp;</p><p><strong>Important things to know before you use this medicine:</strong></p><p>Tell your doctor if you:<strong> </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have eye problems. Fast improvements in blood sugar control may make diabetic eye problems get worse for a short time. The long-term improvements in blood sugar control may ease the eye problems.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have or have had a thyroid disease.</p><p>&nbsp;</p><p><strong>Important things to know while you are using this medicine:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a severe stomach ache which does not go away, tell your doctor &ndash; this could be a sign of inflamed pancreas (acute pancreatitis).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dehydration (loss of fluids from the body) can happen if you are feeling or being sick (nausea or vomiting) or have diarrhoea &ndash; it is important to drink plenty of fluids to stop dehydration.</p><p>&nbsp;</p><p><strong>Skin changes at the injection site</strong></p><p>The injection site should be rotated to help prevent changes to the fatty tissue under the skin, such as skin thickening, skin shrinking or lumps under the skin. The insulin may not work very well if you inject into a lumpy, shrunken or thickened area (see section 3 &lsquo;How to use Xultophy<sup>&reg;</sup>&rsquo;). Tell your doctor if you notice any skin changes at the injection site. Tell your doctor if you are currently injecting into these affected areas before you start injecting in a different area. Your doctor may tell you to check your blood sugar more closely, and to adjust your insulin or your other antidiabetic medications dose.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Do not give this medicine to children or adolescents. There is no experience with Xultophy<sup>&reg;</sup> in children and adolescents under 18&nbsp;years old.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and </strong><strong>Xultophy<sup>&reg;</sup></strong></p><p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. Some medicines affect your blood sugar level &ndash; this may mean your Xultophy<sup>&reg;</sup> dose has to change.</p><p>&nbsp;</p><p>Listed below are the most common medicines, which may affect your Xultophy<sup>&reg;</sup> treatment.</p><p>&nbsp;</p><p><strong>Your blood sugar level may fall if you take:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines for diabetes (tablets or injections)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sulfonamides &ndash; for infections</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anabolic steroids &ndash; such as testosterone</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; beta-blockers &ndash; for high blood pressure. They may make it harder to recognise the warning signs of low blood sugar (see section 4 &lsquo;Warning signs of low blood sugar &ndash; these may come on suddenly&rsquo;)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acetylsalicylic acid (and medicines called &lsquo;salicylates&rsquo;) &ndash; for pain and mild fever</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; monoamine oxidase (MAO) inhibitors &ndash; for depression</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; angiotensin converting enzyme (ACE) inhibitors &ndash; for some heart problems or high blood pressure.</p><p><strong>&nbsp;</strong></p><p><strong>Your blood sugar level may rise if you take:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; danazol &ndash; medicine affecting ovulation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oral contraceptives &ndash; birth control pills</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thyroid hormones &ndash; for thyroid disease</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; growth hormone &ndash; for low levels of growth hormone</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines called &lsquo;glucocorticoids&rsquo; such as cortisone &ndash; for inflammation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines called &lsquo;sympathomimetics&rsquo; such as epinephrine (adrenaline), salbutamol or terbutaline &ndash; for asthma</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; water tablets called &lsquo;thiazides&rsquo; &ndash; for high blood pressure or if your body is holding onto too much water (water retention).</p><p>&nbsp;</p><p><strong>Octreotide and lanreotide</strong> &ndash; used for treatment of acromegaly (a rare illness with too much growth hormone). They may increase or decrease your blood sugar level.</p><p>&nbsp;</p><p><strong>Pioglitazone </strong>&ndash; tablets used for the treatment of type 2 diabetes mellitus.<strong> </strong>Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke, who were treated with pioglitazone and insulin, experienced the development of heart failure. Inform your doctor straight away if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema).</p><p>&nbsp;</p><p><strong>Warfarin or other blood thinners </strong>&ndash; medicines used to prevent clotting of the blood. Tell your doctor if you are taking warfarin or other blood thinners as you might need to have blood tests more often to measure how thick your blood is (called &lsquo;International Normalised Ratio&rsquo; or INR test).</p><p>&nbsp;</p><p><strong>Xultophy<sup>&reg;</sup></strong><strong> with alcohol</strong></p><p>If you drink alcohol, your need for Xultophy<sup>&reg;</sup> may change. Your blood sugar level may either rise or fall. You should therefore monitor your blood sugar level more often than usual.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_b7d3fd78-261e-4ba5-94ab-00dc185ba7e8 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Do not use Xultophy<sup>&reg;</sup> if you are pregnant or plan to become pregnant. Tell your doctor if you are pregnant, think you might be pregnant or are planning to have a baby. It is not known if Xultophy<sup>&reg; </sup>affects the baby.</p><p>&nbsp;</p><p>Do not use Xultophy<sup>&reg;</sup> if you are breast-feeding. It is not known if Xultophy<sup>&reg;</sup> passes into breast milk.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_d7d292ca-d95e-4ade-a26e-34676554977b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Having low or high blood sugar can affect your ability to drive or use any tools or machines. If your blood sugar is low or high, your ability to concentrate or react might be affected. This could be dangerous to yourself or others. Ask your doctor whether you can drive if:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you often get low blood sugar</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you find it hard to recognise low blood sugar.</p><p>&nbsp;</p><p><strong>Important information about some of the ingredients of Xultophy<sup>&reg;</sup></strong><!--[if supportFields]><span
style='mso-bookmark:_Hlk3271003'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Hlk3271003'><b style='mso-bidi-font-weight:normal'><span
lang=EN-GB style='mso-ansi-language:EN-GB'> DOCVARIABLE
vault_nd_b6dde818-4dd4-4bfd-9d74-8cc9567408ac \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-bookmark:_Hlk3271003'></span><span style='mso-element:field-end'></span><![endif]--></p><p>Xultophy<sup>&reg;</sup> contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose. This means that the medicine is essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor, pharmacist or nurse if you are not sure.</p><p>&nbsp;</p><p>If you are blind or have poor eyesight and cannot read the dose counter on the pen, do not use this pen without help. Get help from a person with good eyesight who is trained to use the Xultophy<sup>&reg;</sup> pre-filled pen.</p><p>&nbsp;</p><p><strong>Your doctor will tell you:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; how much Xultophy<sup>&reg;</sup> you will need each day</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; when to check your blood sugar level</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; how to adjust the dose.</p><p>&nbsp;</p><p>Your dose of Xultophy<sup>&reg;</sup> is administered as &lsquo;dose steps&rsquo;. The dose counter on the pen shows the number of dose steps.</p><p>&nbsp;</p><p><strong>Dosing time</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use Xultophy<sup>&reg;</sup> once each day, preferably at the same time every day. Choose a time of the day that works best for you.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If it is not possible to use Xultophy<sup>&reg;</sup> at the same time every day, it can be used at a different time of the day. Make sure to have a minimum of 8&nbsp;hours between the doses.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You do not have to use Xultophy<sup>&reg;</sup> with a meal.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Always follow your doctor&rsquo;s advice for dose and dose adjustment.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you want to change your usual diet, check with your doctor, pharmacist or nurse first as a change in diet may alter your need for Xultophy<sup>&reg;</sup>.</p><p>&nbsp;</p><p><strong>How to handle Xultophy<sup>&reg;</sup> </strong></p><p>Xultophy<sup>&reg;</sup> is a pre-filled dial-a-dose pen.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Xultophy<sup>&reg;</sup> is administered as &lsquo;dose steps&rsquo;. The dose counter on the pen shows the number of dose steps.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; One dose step contains 1&nbsp;unit of insulin degludec and 0.036&nbsp;mg of liraglutide.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The maximum daily dose of Xultophy<sup>&reg;</sup> is 50&nbsp;dose steps (50&nbsp;units of insulin degludec and 1.8&nbsp;mg of liraglutide).</p><p>Carefully read the &lsquo;Instructions on how to use&rsquo; on the other side of this leaflet and use the pen as described.</p><p>Always check the pen label before you inject your medicine to ensure that you use the correct pen.</p><p>&nbsp;</p><p><strong>How to inject</strong></p><p>Before you use Xultophy<sup>&reg;</sup> for the first time, your doctor or nurse will show you how to inject.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Xultophy<sup>&reg;</sup> is given as an injection under the skin (subcutaneously). Do not inject it into a vein or muscle.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The best places to inject are the front of your thighs, upper arms or the front of your waist (abdomen).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change the place within the area where you inject each day to reduce the risk of developing lumps and skin pitting (see section 4).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Always use a new needle for each injection. Re-use of needles may increase the risk of blocked needles leading to inaccurate dosing. Dispose of the needle safely after each use.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use a syringe to remove the solution from the pen to avoid dosing errors and potential overdose.</p><p>&nbsp;</p><p>Detailed instructions for use are on the other side of this leaflet.</p><p>&nbsp;</p><p><strong>Do not use Xultophy<sup>&reg;</sup></strong><strong>:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the pen is damaged or has not been stored correctly (see section 5).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the liquid you can see through the pen window does not look clear and colourless.</p><p>&nbsp;</p><p><strong>Use in elderly patients (65&nbsp;years old or over)</strong></p><p>Xultophy<sup>&reg;</sup> can be used in elderly patients but if you are elderly you may need to check your blood sugar level more often. Talk to your doctor about changes in your dose.</p><p>&nbsp;</p><p><strong>If you have kidney or liver problems</strong></p><p>If you have kidney or liver problems, you may need to check your blood sugar level more often. Talk</p><p>to your doctor about changes in your dose.</p><p><strong>&nbsp;</strong></p><p><strong>If you use more </strong><strong>Xultophy<sup>&reg;</sup> </strong><strong>than you should</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_5bd18da9-bd76-4912-8d77-b4fe81cc54f4 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>If you use more Xultophy<sup>&reg;</sup> than you should, your blood sugar may get low (hypoglycaemia) or you may feel or be sick (nausea or vomiting). If your blood sugar gets low, see the advice in section 4 &lsquo;Low blood sugar (hypoglycaemia)&rsquo;.<!--[if supportFields]><span
lang=EN-GB style='mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_4ee38734-af36-49a3-8b5b-3cef26ab9662 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><strong>If you forget to use </strong><strong>Xultophy<sup>&reg;</sup></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-ansi-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_296fbff4-f389-46bc-9700-d8ba5532b82d \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-ansi-language:
EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>If you forget a dose, inject the missed dose when discovering the mistake, ensuring a minimum of 8&nbsp;hours between doses. If you discover that you missed your previous dose when it is time to take your next regular scheduled dose, do not take a double dose.</p><p>&nbsp;</p><p><strong>If you stop using </strong><strong>Xultophy<sup>&reg;</sup></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-ansi-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_999e9c86-560b-481a-b85b-2ce4e64e88aa \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-ansi-language:
EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Do not stop using Xultophy<sup>&reg;</sup> without talking to your doctor. If you stop using Xultophy<sup>&reg;</sup> this could lead to a very high blood sugar level, see the advice in section 4 &lsquo;High blood sugar (hyperglycaemia)&rsquo;.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following serious side effects may happen with this medicine:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood sugar (very common: may affect more than 1 in 10&nbsp;people).</p><p>If your blood sugar level gets low you may pass out (become unconscious). Serious hypoglycaemia may cause brain damage and may be life-threatening. If you have signs of low blood sugar, take actions to increase your blood sugar level straight away. See advice in &lsquo;Low blood sugar (hypoglycaemia)&rsquo; further down in this section.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious allergic reaction (anaphylactic reaction) (not known: frequency cannot be estimated from the available data).</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a serious allergic reaction to any of the ingredients in Xultophy<sup>&reg;</sup>, stop using Xultophy<sup>&reg;</sup> and see a doctor straight away. The signs of a serious allergic reaction are:</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; local reactions spread to other parts of your body</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; you suddenly feel unwell with sweating</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; you have difficulty breathing</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; you get a fast heartbeat or feel dizzy.</p><p>&nbsp;</p><p><strong>Skin changes at the injection site:</strong></p><p>If you inject insulin at the same place, the fatty tissue may shrink (lipoatrophy) or thicken (lipohypertrophy) (may affect up to 1 in 100&nbsp;people). Lumps under the skin may also be caused by build-up of a protein called amyloid (cutaneous amyloidosis; how often this occurs is not known). The insulin may not work very well if you inject into a lumpy, shrunken or thickened area. Change the injection site with each injection to help prevent these skin changes.</p><p>&nbsp;</p><p>Other side effects include:</p><p><strong>Common</strong> (may affect up to 1 in 10&nbsp;people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;Dizziness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lower appetite, feeling or being sick (nausea or vomiting), diarrhoea, constipation, indigestion (dyspepsia), inflamed lining of the stomach (gastritis), stomach ache, heartburn or bloating &ndash; these usually go away after a few days or weeks.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injection site reactions. The signs may include bruising, bleeding, pain, redness, hives, swelling or itching &ndash; these usually go away after a few days. See your doctor if they do not disappear after a few weeks. Stop using Xultophy<sup>&reg;</sup> and see a doctor straight away if they become serious.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase of pancreatic enzymes, such as lipase and amylase.</p><p>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in 100&nbsp;people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hives (red bumps on your skin that are sometimes itchy).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions (hypersensitivity) such as rash, itching and swelling of the face.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dehydration (loss of fluid from the body) &ndash; it is important to drink plenty of fluids to stop dehydration.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Belching (eructation) and wind (flatulence).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased heart rate.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gallstones.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflamed gallbladder.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change in how things taste.</p><p>&nbsp;</p><p><strong>Not known</strong> (frequency cannot be estimated from the available data)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflamed pancreas (pancreatitis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;Delay in the emptying of the stomach</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of arms or legs (peripheral oedema) &ndash; when you first start using your medicine, your body may keep more water than it should. This causes swelling around your ankles and other joints. This is usually only short-lasting.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;Bowel obstruction, A severe form of constipation with additional symptoms such as stomachache, bloating, vomiting, etc.,</p><p><em>&nbsp;</em></p><p><strong>General effects from diabetes treatment</strong></p><p>&nbsp;</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Low blood sugar (hypoglycaemia)</em></strong></p><p><strong>&nbsp;</strong></p><p><strong>Low blood sugar may happen if you:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drink alcohol</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; exercise more than usual</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eat too little or miss a meal</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; use too much Xultophy<sup>&reg;</sup>.</p><p>&nbsp;</p><p><strong>Warning signs of low blood sugar &ndash; these may come on suddenly</strong></p><p>Headache, slurred speech, fast heartbeat, cold sweat, cool pale skin, feeling sick (nausea), feeling very hungry, shaking, feeling nervous or worried, unusually tired, weak and sleepy or confused, difficulty concentrating, short-lasting changes in your sight.</p><p>&nbsp;</p><p><strong>What to do if you get low blood sugar:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eat glucose tablets or another high sugar snack &ndash; like sweets, biscuits or fruit juice (always carry glucose tablets or a high sugar snack, just in case).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Measure your blood sugar if possible and rest. You may need to measure your blood sugar more than once. This is because improvement in your blood sugar may not happen straight away.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wait until the signs of low blood sugar have gone or when your blood sugar level has settled. Then carry on with your medicine as usual.</p><p>&nbsp;</p><p><strong>What others need to do if you pass out: </strong></p><p>Tell everyone you spend time with that you have diabetes. Tell them what could happen if your blood sugar gets low, including the risk of passing out.</p><p>&nbsp;</p><p>Let them know that if you pass out, they must:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; turn you on your side</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; get medical help straight away</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>not</strong> give you any food or drink &ndash; because you may choke.</p><p>&nbsp;</p><p>You may recover more quickly from passing out if you receive &nbsp;glucagon. This can only be given by someone who knows how to use it.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are given glucagon, you will need sugar or a sugary snack as soon as you come round.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you do not respond to glucagon treatment, you will have to be treated in a hospital.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If severe low blood sugar is not treated over time, it can cause brain damage. This can be short- or long-lasting. It may even cause death.</p><p>&nbsp;</p><p><strong>Talk to your doctor if:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your blood sugar got so low that you passed out</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have used glucagon</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have had low blood sugar a few times recently.</p><p>This is because the dosing of your Xultophy<sup>&reg;</sup> injections, food or exercise may need to be changed.</p><p>&nbsp;</p><p>►&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>High blood sugar (hyperglycaemia)</em></strong></p><p>&nbsp;</p><p><strong>High blood sugar may happen if you:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drink alcohol</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; exercise less than usual</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eat more than usual</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; get an infection or a fever</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have not used enough Xultophy<sup>&reg;</sup>, keep using less Xultophy<sup>&reg;</sup> than you need, forget to use Xultophy<sup>&reg;</sup> or stop using Xultophy<sup>&reg;</sup> without talking to your doctor.</p><p>&nbsp;</p><p><strong>Warning signs of high blood sugar &ndash; these normally appear gradually</strong></p><p>Flushed, dry skin, feeling sleepy or tired, dry mouth, fruity (acetone) breath, urinating more often, feeling thirsty, losing your appetite, feeling or being sick (nausea or vomiting).</p><p>These may be signs of a very serious condition called &lsquo;ketoacidosis&rsquo;. This is a build-up of acid in the blood because the body is breaking down fat instead of sugar. If not treated, this could lead to diabetic coma and eventually death.</p><p>&nbsp;</p><p><strong>What to do if you get high blood sugar:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Test your blood sugar level.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Test your blood or urine for ketones.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Get medical help straight away.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_45d8a84e-8071-4cac-8e53-29f9ea9bb010 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>The National Pharmacovigilance Centre (NPC):</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p>Website: https://ade.sfda.gov.sa</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the pen label and carton after &lsquo;EXP&rsquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p><strong>Before opening</strong></p><p>Store in a refrigerator (2&deg;C to 8&deg;C). Keep away from the freezing element. Do not freeze.</p><p>&nbsp;</p><p><strong>During use</strong></p><p>Do not freeze. You can carry Xultophy<sup>&reg;</sup> with you and keep it at room temperature (no more than 30&deg;C) or in a refrigerator (2&deg;C to 8&deg;C) for up to 21&nbsp;days. The product should be thrown away 21&nbsp;days after first opening.</p><p>&nbsp;</p><p>Always keep the cap on the pre-filled pen when you are not using it in order to protect it from light.</p><p><em>&nbsp;</em></p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What </strong><strong>Xultophy<sup>&reg;</sup></strong><strong> contains </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are insulin degludec and liraglutide. Each mL of solution contains 100&nbsp;units of insulin degludec and 3.6&nbsp;mg liraglutide. Each unused pre-filled pen (3&nbsp;mL) contains 300&nbsp;units of insulin degludec and 10.8&nbsp;mg liraglutide.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are glycerol, phenol, zinc acetate, hydrochloric acid and sodium hydroxide (for pH adjustment), and water for injections. See also section 2 &lsquo;Important information about some of the ingredients of Xultophy<sup>&reg;</sup>&rsquo; for information on sodium.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Xultophy® is a clear and colourless solution.
	Pack sizes of 1, 3, 5 and a multipack containing 10 (2 packs of 5) pens of 3 mL. Not all pack sizes may be marketed.
	

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>Novo Nordisk A/S</p><p>Novo All&eacute;</p><p>DK-2880 Bagsv&aelig;rd, Denmark</p><p>&nbsp;</p><p><strong>Now turn over for information on how to use your pre-filled pen.</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>This is a Medicament</p><p>-&nbsp;&nbsp;&nbsp; Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.</p><p>-&nbsp;&nbsp;&nbsp; Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the pharmacist who sold the medicament.</p><p>-&nbsp;&nbsp;&nbsp; The doctor and the pharmacist are the experts in medicines, their benefits and risks.</p><p>-&nbsp;&nbsp;&nbsp; Do not by yourself interrupt the period of treatment prescribed for you.</p><p>-&nbsp;&nbsp;&nbsp; Do not repeat the same prescription without consulting your doctor.</p><p>-&nbsp;&nbsp;&nbsp; Keep all medicaments out of reach of children.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Council of Arab Health Ministers</strong></p><p><strong>Union of Arab Pharmacists</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Sep-2024 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>فيما يُستخدم زلتوفاي</strong></p><p dir="RTL">يستخدم زلتوفاي<sup> </sup>لتحسين مستويات الغلوكوز (السكر) في الدم لدى المرضى البالغين المصابين بالنوع الثاني من مرض السكري. ترجع إصابتك بمرض السكري لأن جسمك:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينتج ما يكفي من الإنسولين للتحكم في مستوى السكر في دمك، أو</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يمكنه استخدام الإنسولين بصورة ملائمة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف يعمل زلتوفاي</strong></p><p dir="RTL">يحتوي زلتوفاي<sup> </sup>على مادتين فعالتين تساعدان جسمك على التحكم في مستوى السكر في دمك:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنسولين ديجلودِك؛ وهو إنسولين قاعدي طويل المفعول يخفض مستويات السكر في دمك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ليراجلوتايد؛ وهو &quot;أحد نظائر الببتيد الشبيه بالجلوكاجون-1&quot;، ويساعد جسمك على إنتاج المزيد من الإنسولين أثناء الوجبات ويخفض من كمية السكر التي ينتجها الجسم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>زلتوفاي</strong><sup> </sup><strong>وأدوية السكري التي يتم تناولها عن طريق الفم</strong></p><p dir="RTL">يستخدم زلتوفاي<sup> </sup>مع أدوية السكري التي يتم تناولها عن طريق الفم (مثل عقاقير ميتفورمين وبيوجليتازون وسالفونيل يوريا). ويوصف عندما لا تكون هذه الأدوية (التي تُستخدم وحدها أو مع علاج الببتيد الشبيه بالجلوكاجون-1 أو مع الإنسولين القاعدي) كافية للتحكم في مستويات السكر في دمك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة استخدامك علاج الببتيد الشبيه بالجلوكاجون-</strong><strong>1</strong></p><p dir="RTL">عليك إيقاف علاج الببتيد الشبيه بالجلوكاجون-1 قبل شروعك في استخدام زلتوفاي</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حال استخدامك للإنسولين</strong></p><p dir="RTL">عليك إيقاف علاج الإنسولين قبل شروعك في استخدام زلتوفاي</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استخدام زلتوفاي</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-begin'></span> </span></b><span lang=DA
dir=LTR style='mso-bidi-font-size:11.0pt;mso-bidi-font-weight:bold'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
lang=DA style='mso-bidi-font-size:11.0pt'><span dir=RTL></span><span dir=RTL></span>
</span></b><span lang=DA dir=LTR style='mso-bidi-font-size:11.0pt;mso-bidi-font-weight:
bold'>VAULT_ND_c1c60423-d852-439c-bafe-2406623e739e \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
lang=DA style='mso-bidi-font-size:11.0pt'><span dir=RTL></span><span dir=RTL></span>
</span></b><b style='mso-ansi-font-weight:normal'><span lang=AR-SA
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت شديد الحساسية لإنسولين ديجلودِك أو ليراجلوتايد أو أي مكونات أخرى تدخل في تركيب هذا الدواء (الواردة في القسم 6).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-begin'></span> </span></b><span lang=DA
dir=LTR style='mso-bidi-font-size:11.0pt;mso-bidi-font-weight:bold'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
lang=DA style='mso-bidi-font-size:11.0pt'><span dir=RTL></span><span dir=RTL></span>
</span></b><span lang=DA dir=LTR style='mso-bidi-font-size:11.0pt;mso-bidi-font-weight:
bold'>VAULT_ND_4ff24c0d-1bcb-4897-ab85-7814c0d9f2f8 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
lang=DA style='mso-bidi-font-size:11.0pt'><span dir=RTL></span><span dir=RTL></span>
</span></b><b style='mso-ansi-font-weight:normal'><span lang=AR-SA
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">استشر الطبيب أو الصيدلي أو الممرض قبل استخدام زلتوفاي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول سالفونيل يوريا كذلك (مثل جليمبيرايد أو جليبنكلامايد)، فقد يطلب منك طبيبك تخفيض جرعة سالفونيل يوريا بحسب مستويات السكر في دمك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم زلتوفاي<sup> </sup>إذا كنت مصاباً بالنوع الأول من مرض السكري أو إذا كنت مصاباً بالحماض الكيتوني (حالة يتراكم فيها الحمض في الدم).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يوصى باستعمال زلتوفاي<sup> </sup>عند المرضى المصابين بمرض التهاب الأمعاء أو يعانون من تأخر الإفراغ المعدي (الخزل المَعدي السكري).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعلم أنك ستخضع لعملية جراحية ستكون فيها تحت تأثير التخدير (نائم)، يُرجى إخبار طبيبك بأنك تتناول عقار زلتوفاي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">انتبه خصيصاً لما يلي عند استخدام زلتوفاي:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض نسبة السكر في الدم (هبوط سكر الدم) - في حالة الانخفاض الشديد في نسبة السكر في الدم، اتبع الإرشادات الواردة في القسم 4<em> </em><em>&quot;انخفاض نسبة السكر في الدم (هبوط سكر الدم)&quot;.</em></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع نسبة السكر في الدم (ارتفاع سكر الدم) - في حالة ارتفاع نسبة السكر في دمك، اتبع الإرشادات الواردة في القسم 4<em> </em><em>&quot;ارتفاع نسبة السكر في الدم (ارتفاع سكر الدم)&quot;.</em></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &rlm;‫التأكد من استخدام الدواء الصحيح - احرص دائماً على التحقق من الملصق على قلم الحقن قبل كل حقنة لتجنب الخلط بطريق الخطأ بين زلتوفاي<sup> </sup><sup>&nbsp;</sup>والمنتجات الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أشياء مهمة يجب أن تعرفها قبل استخدامك هذا الدواء:</strong></p><p dir="RTL">أخبر طبيبك في الحالات التالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك مشاكل في العين. قد يؤدي التحسن السريع في السيطرة على نسبة السكر في الدم إلى تدهور لفترة قصيرة في مشاكل العين الناتجة عن مرض السكري. قد يؤدي التحسن طويل الأجل في السيطرة على نسبة السكر في الدم إلى التخفيف من مشاكل العين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً حالياً بمرض الغدة الدرقية أو إذا أصبت به سابقاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أشياء مهمة يجب أن تعرفها أثناء استخدامك هذا الدواء:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من وجع شديد بالبطن لا يخف، أبلغ طبيبك، فقد يكون ذلك علامة على التهاب البنكرياس (الالتهاب الحاد للبنكرياس).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن يحدث الجفاف (افتقار الجسم إلى السوائل) إذا كنت تشعر بالغثيان أو القيء أو إذا كنت مصاباً بالإسهال، من المهم أن تشرب السوائل بوفرة لإيقاف الجفاف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تغيرات جلدية في موضع الحقن</strong></p><p dir="RTL">يجب تغيير موضع الحقن باستمرار للمساعدة في منع حدوث تغييرات في الأنسجة الدهنية تحت الجلد، مثل سماكة الجلد أو انكماش الجلد أو وجود كتل تحت الجلد. قد لا يعمل الإنسولين جيداً إذا تم الحقن في منطقة متكتلة أو منكمشة أو سميكة (انظر القسم 3 &quot;كيفية استخدام زلتوفاي&quot;). أخبر طبيبك إذا لاحظت أي تغيرات جلدية في موضع الحقن. أخبر طبيبك إذا كنت تحقن حالياً في هذه المناطق المصابة قبل البدء في الحقن في منطقة مختلفة. قد يطلب منك طبيبك فحص نسبة السكر في الدم عن كثب، وتعديل جرعة الإنسولين أو الأدوية الأخرى المضادة لمرض السكر.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا تقم بإعطاء هذا الدواء للأطفال أو المراهقين. لا توجد أي تجارب بشأن استخدام زلتوفاي مع الأطفال والمراهقين الأقل من 18 عاماً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وزلتوفاي</strong></p><p dir="RTL">يُرجى إخبار الطبيب أو الصيدلي أو الممرض إذا كنت تتناول أدوية أخرى أو تناولت أي أدوية أخرى مؤخراً أو قد تتناول أدوية أخرى في المستقبل. تؤثر بعض الأدوية على مستوى السكر في دمك، وقد يعني ذلك ضرورة تغيير جرعة زلتوفاي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">فيما يلي الأدوية الأكثر شيوعاً التي قد تؤثر في علاجك بزلتوفاي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد ينخفض مستوى السكر في دمك إذا تناولت:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى لمرض السكري (أقراص أو حقن)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سلفوناميدات - للعدوى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; منشطات بنائية - مثل التيستوستيرون</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاصرات البيتا - لارتفاع ضغط الدم. فقد تؤدي إلى صعوبة التعرف على العلامات التحذيرية لانخفاض السكر في الدم (اطلع على قسم 4 &quot;&rlm;العلامات التحذيرية لانخفاض السكر في الدم - قد تظهر هذه العلامات فجأة<em>&quot;</em>)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمض الأسيتيل ساليسيليك (والأدوية التي يُطلق عليها &quot;مجموعة الساليسيلات&quot;) - للألم والحمى الخفيفة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مُثَبِّطَات أُكسيدازِ أُحادِيِّ الأَمين (MAOI) - للاكتئاب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مُثَبِّطَات الإِنْزيم المُحَوِّل للأَنْجِيوتَنْسين (ACE) - لبعض مشاكل القلب أو ضغط الدم المرتفع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد يرتفع مستوى السكر في الدم إذا تناولت:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دانازول - دواء يؤثر على الإباضة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وسائل منع الحمل عن طريق الفم - حبوب منع الحمل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هرمونات الغدة الدرقية - لأمراض الغدة الدرقية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هرمون النمو - لانخفاض مستويات هرمون النمو</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي يُطلق عليها &quot;الأدوية القشرانية السكرية&quot;، مثل &quot;الكورتيزون&quot; - للالتهاب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي يطلق عليها المحاكيات السمبثاوية، مثل الإبِينيفرِين (الأدرينالين)، أو السالبوتامول أو التيربوتالين - للربو</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص مدرة للبول يُطلق عليها &quot;الثيازيدات&quot; - لضغط الدم المرتفع أو إذا كان جسمك يحتفظ بكمية أكثر من الماء (احتباس الماء).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأوكتريوتايد واللانريوتايد</strong> - يستعملان لعلاج تضخم الأطراف (مرض نادر ينطوي على فرط شديد في هرمون النمو). وقد يتسببان في زيادة أو نقصان مستوى السكر بالدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بيوجليتازون </strong>- أقراص تستخدم لعلاج النوع الثاني من السكري.<strong> </strong>تعرض بعض المرضى المصابين بالنوع الثاني من مرض السكري وأمراض القلب لفترات طويلة أو المصابين بسكتة دماغية سابقاً وعولِجوا ببيوجليتازون مع الإنسولين بفشل القلب. أخبر طبيبك على الفور إذا ظهرت عليك علامات قصور القلب مثل صعوبة في التنفس غير معتادة أو زيادة سريعة في الوزن أو تورم موضعي (وذمة).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>وارفارين أو غير ذلك من مسيلات الدم </strong>- أدوية تستخدم لمنع تجلط الدم. أخبر طبيبك إذا كنت تتناول وارفارين أو غيره من مسيلات الدم، فقد تحتاج إلى إجراء اختبارات الدم بصورة أكثر تواتراً لقياس مدى تخثر دمك (وهو ما يسمى &quot;النسبة الدولية المعيارية&quot; أو اختبار INR).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>زلتوفاي مع الكحول</strong></p><p dir="RTL">إذا كنت تتناول الكحول؛ فقد يتغير احتياجك لعقار زلتوفاي. وذلك لأن مستوى السكر في الدم لديك إما أن يرتفع وإما أن ينخفض. لذلك يجب عليك مراقبة مستوى السكر في الدم أكثر من المعتاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-begin'></span> </span></b><span lang=DA
dir=LTR style='mso-bidi-font-size:11.0pt;mso-bidi-font-weight:bold'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
lang=DA style='mso-bidi-font-size:11.0pt'><span dir=RTL></span><span dir=RTL></span>
</span></b><span lang=DA dir=LTR style='mso-bidi-font-size:11.0pt;mso-bidi-font-weight:
bold'>VAULT_ND_c84b3252-7639-49f2-81ce-02e99532319c \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
lang=DA style='mso-bidi-font-size:11.0pt'><span dir=RTL></span><span dir=RTL></span>
</span></b><b style='mso-ansi-font-weight:normal'><span lang=AR-SA
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">لا تستخدمي زلتوفاي &rlm;إذا كنِت حاملاً أو كنِت تخططين للإنجاب. أخبري طبيبِك &rlm;إذا كنِت حاملاً أو تظنين أنك قد تكونين حاملاً أو كنِت تخططين للإنجاب. ليس من المعلوم ما إذا كان زلتوفاي يؤثر على الجنين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ولا تستخدمي زلتوفاي في حالة الرضاعة الطبيعية. لأنه من غير المعروف ما إذا كان زلتوفاي ينتقل إلى حليب الأم أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-begin'></span> </span></b><span lang=DA
dir=LTR style='mso-bidi-font-size:11.0pt;mso-bidi-font-weight:bold'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
lang=DA style='mso-bidi-font-size:11.0pt'><span dir=RTL></span><span dir=RTL></span>
</span></b><span lang=DA dir=LTR style='mso-bidi-font-size:11.0pt;mso-bidi-font-weight:
bold'>VAULT_ND_9089449b-d927-4cdc-bc31-e771d8282c0e \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
lang=DA style='mso-bidi-font-size:11.0pt'><span dir=RTL></span><span dir=RTL></span>
</span></b><b style='mso-ansi-font-weight:normal'><span lang=AR-SA
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">إن الزيادة أو النقص في سكر الدم يمكن أن يؤثر في قدرتك على قيادة المركبات أو استخدام أي أدوات أو آلات. حيث إنه في حالة الانخفاض أو الارتفاع في سكر الدم، قد تتأثر قدرتك على التركيز أو التفاعل. ويمكن أن يشكل هذا خطورة على سلامتك أو سلامة الآخرين. اسأل طبيبك إذا كان بإمكانك القيادة وذلك في حالة:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرضك في الغالب لانخفاض السكر في الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة ملاحظة انخفاض السكر في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات مهمة عن بعض مكونات زلتوفاي</strong></p><p dir="RTL">يحتوي زلتوفاي على أقل من 1 مليمول صوديوم (23 ملغ) لكل جرعة. هذا يعني أن الدواء &quot;خالي من الصوديوم&quot; بشكل أساسي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب استعمال هذا الدواء دائماَ كما أخبرك طبيبك تماماً. ويجب استشارة الطبيب أو الصيدلي أو الممرض في حالة الشك بشأن طريقة استخدامه على الوجه الصحيح.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&rlm;‫إذا كنت كفيفاً أو تعاني من ضعف البصر ولا تستطيع قراءة عداد الجرعة على القلم، فلا تستخدم هذا المنتج الطبي دون مساعدة. &rlm;‫وينبغي طلب المساعدة من شخص يتمتع ببصر جيد ومدرب على استخدام قلم زلتوفاي المعبأ مسبقاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>سوف يخبرك طبيبك:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بمقدار الجرعة التي سوف تحتاج إليها من زلتوفاي كل يوم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متى تفحص مستوى السكر في دمك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيفية تعديل الجرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ستعطى جرعتك من زلتوفاي في صورة &quot;جرعات تدريجية&quot;. يُظهر عداد الجرعة بالقلم عدد الجرعات التدريجية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توقيت الجرعات</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُستخدم زلتوفاي مرة واحدة في اليوم ويفضل في وقت واحد كل يوم. قم باختيار الوقت الأنسب لك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة عدم إمكانية استخدام زلتوفاي في نفس الوقت كل يوم، يمكن أخذ الجرعة في وقت آخر من اليوم. يُرجى التأكد من مرور مدة 8 ساعات على الأقل بين كل جرعة والتي تليها.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تحتاج لاستخدام زلتوفاي مع الوجبات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي دائماً اتباع نصيحة طبيبك بشأن الجرعة وتعديل الجرعة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أردت تغيير نظامك الغذائي المعتاد، فينبغي استشارة طبيبك أو الصيدلي أو الممرض أولاً حيث إن تغيير النظام الغذائي قد يؤدي إلى تغيير الجرعة التي تحتاج إليها من زلتوفاي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف تتعامل مع زلتوفاي</strong></p><p dir="RTL">زلتوفاي هو قلم معبأ مسبقاً للحقن بطريقة ضبط الجرعة ببكرة دوارة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُعطى زلتوفاي في صورة &quot;جرعات تدريجية&quot;. يُظهر عداد الجرعة بالقلم عدد الجرعات التدريجية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحتوي الجرعة التدريجية الواحدة على وحدة واحدة من إنسولين ديجلودِك و0.036 ملجم من ليراجلوتايد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة القصوى من زلتوفاي هي 50 جرعة تدريجية (50 وحدة من إنسولين ديجلودِك و1.8 ملجم من ليراجلوتايد).</p><p dir="RTL">اقرأ بدقة &quot;التعليمات الخاصة بكيفية الاستعمال&quot; على الجانب الآخر من هذه النشرة واستخدم القلم بالطريقة الموصوفة.</p><p dir="RTL">تحقق دائماً من الملصق على القلم قبل حقن دوائك للتأكد من أنك تستخدم القلم الصحيح.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية الحقن</strong></p><p dir="RTL">قبل استعمال زلتوفاي لأول مرة، سيوضح لك طبيبك أو الممرض كيفية الحقن.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تؤخذ جرعة زلتوفاي كحقنة تحت الجلد. لا تحقن في الأوردة ولا في العضل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أفضل أماكن في الجسم للحقن هي الفخذ والجزء العلوي من الذراع ومقدمة الخصر(البطن).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب تغيير الموضع في المنطقة التي تَحقن فيها كل يوم للحد من خطر حدوث تكتلات أو نقر في الجلد (انظر القسم 4).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &rlm;‫يجب دوماً استخدام إبرة جديدة في كل عملية حقن. &rlm;‫إن إعادة استخدام الإبر قد تزيد من مخاطر انسداد الإبر، والتي تؤدي بدورها إلى عدم دقة الجرعة. تخلص من الإبرة بشكل آمن بعد كل استخدام.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &rlm;‫لا تستخدم حقنة لإزالة المحلول من القلم، وذلك لتجنب الخطأ في الجرعات أو احتمالية أخذ جرعة زائدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">توجد تعليمات مفصلة بخصوص الاستخدام على الجانب الآخر من هذه النشرة<em>.</em></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>موانع استخدام زلتوفاي</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة تلف القلم أو عدم تخزينه بطريقة صحيحة (انظر القسم 5).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان السائل الذي يمكنك إبصاره من خلال نافذة القلم لا يبدو صافٍ وعديم اللون.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستعمال في المرضى كبار السن (</strong><strong>65</strong><strong> عاماً أو أكثر)</strong></p><p dir="RTL">يمكن استخدام زلتوفاي مع المرضى كبار السن، ولكن قد يحتاج المريض كبير السن إلى فحص مستوى السكر في الدم بمعدل أكثر تكراراً. ينبغي استشارة طبيبك بشأن تغيير الجرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت تعاني من مشاكل في الكلى أو الكبد</strong></p><p dir="RTL">إذا كنت تعاني من مشاكل بالكلى أو الكبد، فقد تحتاج إلى زيادة وتيرة فحص مستوى السكر بالدم. ينبغي استشارة طبيبك بشأن تغيير الجرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة تناول جرعة زائدة من زلتوفاي عن الجرعة الموصوفة</strong><!--[if supportFields]><b style='mso-ansi-font-weight:normal'><span
lang=AR-SA style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
</span></b><span lang=DA dir=LTR style='mso-bidi-font-size:11.0pt;mso-bidi-font-weight:
bold'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span lang=DA style='mso-bidi-font-size:
11.0pt'><span dir=RTL></span><span dir=RTL></span> </span></b><span lang=DA
dir=LTR style='mso-bidi-font-size:11.0pt;mso-bidi-font-weight:bold'>VAULT_ND_bc1b8661-b584-4a7d-b4e2-22cde7eb1993
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span lang=DA style='mso-bidi-font-size:
11.0pt'><span dir=RTL></span><span dir=RTL></span> </span></b><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">في حالة تناول جرعة زائدة من زلتوفاي عن الجرعة الموصوفة، قد ينخفض مستوى السكر في دمك (هبوط سكر الدم) أو قد تشعر بالتوعك (غثيان أو قيء). في حالة انخفاض نسبة السكر في الدم، اتبع الإرشادات الواردة في القسم 4 &quot;انخفاض السكر في الدم (هبوط سكر الدم)&quot;.<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
</span><span lang=DA dir=LTR style='mso-bidi-font-size:11.0pt'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span lang=DA style='mso-bidi-font-size:
11.0pt'><span dir=RTL></span><span dir=RTL></span> </span><span lang=DA
dir=LTR style='mso-bidi-font-size:11.0pt'>VAULT_ND_158d89c4-c78f-4a0c-a349-c3c3b3409985
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span lang=DA
style='mso-bidi-font-size:11.0pt'><span dir=RTL></span><span dir=RTL></span> </span><span
lang=AR-SA style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة نسيان جرعة زلتوفاي</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><sup><span lang=AR-SA style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-begin'></span> </span></sup></b><sup><span
lang=DA dir=LTR style='mso-bidi-font-size:11.0pt;mso-bidi-font-weight:bold'>DOCVARIABLE</span></sup><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><sup><span
lang=DA style='mso-bidi-font-size:11.0pt'><span dir=RTL></span><span dir=RTL></span>
</span></sup></b><sup><span lang=DA dir=LTR style='mso-bidi-font-size:11.0pt;
mso-bidi-font-weight:bold'>VAULT_ND_39a5ae58-098c-4634-b00e-45e2a01c57e2 \*
MERGEFORMAT</span></sup><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><sup><span lang=DA style='mso-bidi-font-size:
11.0pt'><span dir=RTL></span><span dir=RTL></span> </span></sup></b><b
style='mso-ansi-font-weight:normal'><sup><span lang=AR-SA style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-separator'></span></span></sup></b><![endif]--><strong><sup>&nbsp;</sup></strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><sup><span lang=AR-SA style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-end'></span></span></sup></b><![endif]--></p><p dir="RTL">في حالة نسيان جرعة؛ قم بحقن الجرعة المنسية عند تذكرها، مع التأكد من مرور 8 ساعات بين كل جرعة والتي تليها. وإذا اكتشفت أنك نسيت جرعة مضى وقتها وقد حان وقت جرعة أخرى، فلا تأخذ جرعة مزدوجة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة التوقف عن استخدام دواء زلتوفاي</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><sup><span lang=AR-SA style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-begin'></span> </span></sup></b><sup><span
lang=DA dir=LTR style='mso-bidi-font-size:11.0pt;mso-bidi-font-weight:bold'>DOCVARIABLE</span></sup><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><sup><span
lang=DA style='mso-bidi-font-size:11.0pt'><span dir=RTL></span><span dir=RTL></span>
</span></sup></b><sup><span lang=DA dir=LTR style='mso-bidi-font-size:11.0pt;
mso-bidi-font-weight:bold'>VAULT_ND_e52d6bac-82ec-4159-98d0-586c0d4200bb \*
MERGEFORMAT</span></sup><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><sup><span lang=DA style='mso-bidi-font-size:
11.0pt'><span dir=RTL></span><span dir=RTL></span> </span></sup></b><b
style='mso-ansi-font-weight:normal'><sup><span lang=AR-SA style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-separator'></span></span></sup></b><![endif]--><strong><sup>&nbsp;</sup></strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><sup><span lang=AR-SA style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-end'></span></span></sup></b><![endif]--></p><p dir="RTL">لا تتوقف عن استخدام زلتوفاي دون استشارة طبيبك. في حالة التوقف عن تناول زلتوفاي، قد يحدث ارتفاع شديد في مستوى السكر في الدم لديك، انظرالى الإرشادات في القسم 4 &quot;&rlm;ارتفاع السكر في الدم (ارتفاع سكر الدم)&quot;<em>.</em></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى بشأن استخدام هذا الدواء، ينبغي استشارة طبيبك أو الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-bidi-font-size:
11.0pt;mso-fareast-font-family:Verdana'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL"><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-bidi-font-size:
11.0pt;mso-fareast-font-family:Verdana'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">مثل كل الأدوية، يمكن أن يسبب هذا الدواء آثاراً جانبية وإن كانت لا تحدث مع جميع الأشخاص الذين يستخدمونه. قد تحدث الآثار الجانبية الخطيرة التالية مع تناول هذا الدواء:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&rlm;&rlm;&rlm;</strong>انخفاض السكر في الدم (شائعة جداً: قد تصيب أكثر من شخص واحد من بين 10 أشخاص)</p><p dir="RTL">إذا حدث انخفاض في مستوى سكر الدم لديك، فقد تفقد الوعي. قد تسبب حالة هبوط السكر الشديد في الدم تلف المخ وقد تكون مهددة للحياة. إذا حدثت أي علامة من علامات انخفاض سكر الدم لديك، فقم على الفور بالتدابير اللازمة لزيادة مستوى السكر في الدم لديك. راجع التعليمات الواردة أدناه في هذا القسم &quot;انخفاض السكر في الدم (هبوط سكر الدم)&quot; .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية خطيرة (تفاعل تحسسي) (غير معروفة: لا يمكن تقدير معدل التكرار من البيانات المتاحة)</p><p dir="RTL">إذا كنت تعاني من حساسية شديدة لأي من مكونات زلتوفاي، فيجب التوقف عن استخدام زلتوفاي واستشارة الطبيب على الفور. علامات الحساسية الخطيرة هي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتشار ردود الفعل الموضعية إلى أجزاء أخرى من الجسم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور المفاجئ بالإعياء مع التعرق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة نبض القلب أو الشعور بالدوار.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تغيرات جلدية في موضع الحقن:</strong></p><p dir="RTL">إذا حقنت الإنسولين في نفس المكان، فقد تتقلص الأنسجة الدهنية في موضع الحقن (الحثل الشحمي) أو تتضخم (التكتل الشحمي) (قد يصيب حتى شخص واحد من كل 100 شخص). قد يحدث التكتل تحت الجلد أيضاً بسبب تراكم بروتين يسمى النشواني (الداء النشواني الجلدي، ومعدل تكرار حدوث ذلك غير معروف). قد لا يعمل الإنسولين جيداً إذا تم الحقن في منطقة متكتلة أو منكمشة أو سميكة. يجب تغيير موضع الحقن مع كل حقنة للمساعدة في منع هذه التغيرات الجلدية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">تتضمن الآثار الجانبية الأخرى:</p><p dir="RTL"><strong>شائعة </strong>(قد تصيب حتى شخص واحد من بين 10 أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الشهية، الشعور بالتوعك (الغثيان أو القيء)، الإسهال، الإمساك، سوء الهضم (عسر الهضم)، التهاب بطانة المعدة (التهاب المعدة)، آلام في المعدة، حرقة في المعدة أو الانتفاخ - عادةً ما يختفي ذلك خلال بضعة أيام أو أسابيع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات موضع الحقن. قد تشمل هذه التفاعلات الكدمات، النزيف، الألم، الاحمرار، الشرى، التورم أو الحكة - وعادةً ما تختفي بعد بضعة أيام. ينبغي استشارة طبيبك إذا لم تزل هذه الأعراض بعد عدة أسابيع. ينبغي التوقف عن استخدام زلتوفاي واستشارة الطبيب على الفور في حالة تفاقم هذه الأعراض.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في إنزيمات البنكرياس، مثل الليبيز والأميليز.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة </strong>(قد تصيب حتى شخص واحد من بين 100 شخص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شرى (نتوءات حمراء بجلدك وقد تسبب الحكة).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية (فرط الحساسية)، مثل الطفح الجلدي والحكة وتورم الوجه.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجفاف (افتقار الجسم إلى السائل) - من المهم أن تشرب السوائل بوفرة لإيقاف الجفاف.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التجشؤ (خروج الغازات من الفم) والريح (الانتفاخ بسبب الغازات).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة معدل ضربات القلب.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحصوات الصفراوية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المرارة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيير في طعم الأشياء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">غير معروفة (لا يمكن تقدير معدل حدوثها من البيانات المتاحة)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأخر تفريغ المعدة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الذراعين أو الساقين (الوذمة الطرفية) - عند بدء استعمال الدواء لأول مرة، قد يخزن الجسم كمية أكبر مما ينبغي من الماء. ويسبب هذا تورماً حول الكاحلين والمفاصل الأخرى. ويكون هذا العارض مؤقتاً في العادة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;انسداد الأمعاء، وهو شكل حاد من أشكال الإمساك مع أعراض إضافية مثل آلام المعدة والانتفاخ والتقيؤ وما إلى ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات عامة ناشئة عن علاج مرض السكري</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>►</strong><strong><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &rlm;&rlm;انخفاض السكر في الدم (هبوط سكر الدم)</em></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد يحدث انخفاض السكر في الدم إذا:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شربت الكحول</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مارست التمارين أكثر من المعتاد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناولت كمية من الطعام أقل من اللازم أو لم تتناول إحدى الوجبات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدمت جرعة زائدة من زلتوفاي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>العلامات التحذيرية لانخفاض السكر في الدم - قد تظهر هذه العلامات فجأة</strong></p><p dir="RTL">الصداع، ثقل اللسان، سرعة ضربات القلب، عرق بارد، بشرة باردة شاحبة، شعور بالغثيان، شعور بالجوع الشديد، رعشة أو الشعور بالعصبية أو القلق، الشعور بالتعب بشكل غير معتاد، الضعف والنعاس أو الارتباك، صعوبة في التركيز، تغيرات في الرؤية لفترة قصيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما يجب فعله إذا تعرضت لانخفاض السكر في الدم:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول أقراص الجلوكوز أو تناول وجبة خفيفة غنية بالسكر، مثل البسكويت أو الحلويات أو عصير الفاكهة (دائماً احمل في حقيبتك أقراص الجلوكوز أو وجبة خفيفة غنية بالسكر، فقد تحتاج إليها).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي قياس مستوى السكر في الدم وأخذ قسط من الراحة. قد تحتاج لقياس مستوى السكر في الدم أكثر من مرة. وهذا لأن التحسن في مستوى السكر في الدم لا يحدث على الفور.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتظر حتى تختفي علامات انخفاض السكر في الدم أو عندما يستقر مستوى السكر في الدم. ثم تابع أخذ جرعة الدواء كالمعتاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما يحتاج الآخرين لفعله إذا فقدت الوعي:</strong></p><p dir="RTL">أخبر جميع الأشخاص الذين تقضي وقتك معهم بأنك تعاني من مرض السكري. أخبرهم بالأعراض التي يمكن أن تحدث في حالة الانخفاض في سكر الدم لديك بما في ذلك احتمال دخولك في غيبوبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبرهم بأنه في حالة دخولك في غيبوبة، يجب عليهم القيام بما يلي:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وضعك على جنبك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طلب المساعدة الطبية لك على الفور</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>عدم</strong> إعطائك أي أطعمة أو مشروبات لأنه قد يصيبك بالاختناق.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن تتعافى بسرعة من الغيبوبة إذا تلقيت جلوكاجون. يجب ألا تأخذ هذه الحقنة إلا بواسطة شخص متخصص يعرف كيفية استخدامها.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة حقنك بحقنة جلوكاجون؛ فستحتاج إلى أخذ جلوكوز أو تناول مأكولات سكرية بمجرد أن تستعيد وعيك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم تحدث لديك استجابة للعلاج بجلوكاجون، فسيلزم تلقي العلاج في مستشفى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم تُعالج حالة الانخفاض الشديد في سكر الدم مع مرور الوقت، فيمكن أن تسبب تلفاً في المخ. قد يكون هذا الأثر قصير المدى أو طويل المدى. وقد تؤدي هذه الحالة إلى الوفاة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ينبغي استشارة طبيبك في الحالات التالية:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانخفاض الشديد في سكر الدم لدرجة حدوث غيبوبة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدام جلوكاجون</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إصابتك بانخفاض في سكر الدم لعدة مرات مؤخراً.</p><p dir="RTL">وهذا لأن حالتك قد تتطلب تعديل جرعة الحقن بزلتوفاي<sup> </sup>أو الوجبات الغذائية أو التمارين الرياضية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>►</strong><strong><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع السكر في الدم (ارتفاع سكر الدم)</em></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد يحدث ارتفاع السكر في الدم إذا:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شربت الكحول</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مارست تمارين أقل من المعتاد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناولت أكثر من المعتاد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة الإصابة بالعدوى أو الحمى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم تستخدم كمية كافية من زلتوفاي أو إذا استمر استخدامك لكمية أقل مما ينبغي من زلتوفاي أو إذا نسيت استخدام زلتوفاي أو إذا أوقفت استخدام زلتوفاي دون استشارة طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>العلامات التحذيرية لارتفاع السكر في الدم - هذه العلامات عادةً ما تظهر بشكلٍ تدريجي</strong></p><p dir="RTL">احتقان الدم، جفاف الجلد، الشعور بالنعاس أو التعب، جفاف الفم، رائحة النفس تشبه رائحة الفاكهة (أسيتون)، التبول كثيراً، الشعور بالظمأ، فقدان الشهية، الشعور أو الإصابة بالغثيان (الغثيان أو التقيؤ).</p><p dir="RTL">قد تكون هذه أعراض حالة خطيرة جداً تُسمى &quot;الحماض الكيتوني&quot;. وهذه الحالة عبارة عن تراكم أحماض في الدم لأن الجسم يقوم بتكسير الدهون بدلاً من السكر. إذا لم تُعالج، فقد تؤدي إلى غيبوبة سكر والوفاة في آخر الأمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما يجب فعله إذا تعرضت لارتفاع مستوى السكر في الدم:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قياس مستوى السكر في الدم لديك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فحص الكيتونات في البول.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طلب المساعدة الطبية على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong><!--[if supportFields]><b style='mso-ansi-font-weight:
normal'><span lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-fareast-font-family:
Verdana'><span style='mso-element:field-begin'></span> </span></b><span
lang=DA dir=LTR style='mso-bidi-font-size:11.0pt;mso-fareast-font-family:Verdana;
mso-bidi-font-weight:bold'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><b style='mso-ansi-font-weight:normal'><span lang=DA
style='mso-bidi-font-size:11.0pt;mso-fareast-font-family:Verdana'><span
dir=RTL></span><span dir=RTL></span> </span></b><span lang=DA dir=LTR
style='mso-bidi-font-size:11.0pt;mso-fareast-font-family:Verdana;mso-bidi-font-weight:
bold'>VAULT_ND_a7ac44cf-b023-4ee9-becf-e6c96a46afdc \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
lang=DA style='mso-bidi-font-size:11.0pt;mso-fareast-font-family:Verdana'><span
dir=RTL></span><span dir=RTL></span> </span></b><b style='mso-ansi-font-weight:
normal'><span lang=AR-SA style='mso-bidi-font-size:11.0pt;mso-fareast-font-family:
Verdana'><span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='mso-bidi-font-size:
11.0pt;mso-fareast-font-family:Verdana'><span style='mso-element:field-end'></span></span></b><![endif]--></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>المركز الوطني للتيقظ والسلامة الدوائية:</p><p>&nbsp;فاكس: 2057662-11-966+</p><p>للاتصال بالمركز الموحد للهيئة العامة للغذاء والدواء: 19999</p><p>بريد الالكتروني: npc.drug@sfda.gov.sa</p><p>الموقع الالكتروني: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">يُحفظ هذا الدواء بعيداً عن متناول ومرأى الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المطبوع على ملصق قلم الحقن والعلبة الكرتونية بعد كلمة &quot;Expiry&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قبل الفتح</strong></p><p dir="RTL">يُخزن الدواء في الثلاجة (عند درجة حرارة 2 إلى 8 درجات مئوية). يُحفظ الدواء بعيداً عن وحدة التجميد. يُراعى عدم التجميد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أثناء الاستعمال</strong></p><p dir="RTL">يُراعى عدم التجميد. يمكنك أن تحمل زلتوفاي معك والاحتفاظ به في درجة حرارة الغرفة (لا تزيد على 30 درجة مئوية) أو في الثلاجة (في درجة حرارة 2 إلى 8 درجات مئوية) لمدة تصل إلى 21 يوماً. يجب التخلص من هذا المنتج بعد 21 يوماً من فتحه لأول مرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احرص دائماً على وضع الغطاء على قلم الحقن المعبأ مسبقاً في حال عدم استخدام القلم، وذلك لحمايته من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي بشأن كيفية التخلص من الأدوية التي لم تعد تستعملها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات </strong><strong>زلتوفاي</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي إنسولين ديجلودِك وليراجلوتايد. يحتوي كل مل من المحلول على 100 وحدة من إنسولين ديجلودِك و3.6 ملجم من ليراجلوتايد. &rlm;يحتوي كل قلم حقن معبأ مسبقاً (3 مل) وغير مستخدم على 300 وحدة من إنسولين ديجلودِك و10.8 ملجم من ليراجلوتايد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: جليسرول، فينول، أسيتات الزنك، حمض الهيدروكلوريك وهيدروكسيد الصوديوم (لتعديل درجة الحموضة) وماء للحقن. انظر أيضًا القسم 2 &quot;معلومات مهمة حول بعض مكونات زلتوفاي&quot; للحصول على معلومات عن الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل زلتوفاي ومحتويات العبوة</strong></p><p dir="RTL">زلتوفاي هو محلول صافٍ عديم اللون.</p><p dir="RTL">أحجام العبوات هي قلم واحد و3 أقلام و5 أقلام بكمية 3 مل. &rlm; قد لا تكون جميع أحجام العبوات مطروحة في السوق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">Novo Nordisk A/S</p><p dir="RTL">Novo All&eacute;</p><p dir="RTL">DK-2880 Bagsv&aelig;rd</p><p dir="RTL">Denmark</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p dir="RTL">إن هذا الدواء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدواء مستحضر يؤثر على صحتك واستهلاكه خلافاً للتعليمات يعرضك للخطر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلي الذي صرفها لك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن الطبيب والصيدلي هما الخبيران في الدواء وبنفعه وضرره.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تكرر صرف الدواء بدون استشارة الطبيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تترك الأدوية في متناول أيدي الأطفال.</p></td></tr></tbody></table><p dir="RTL">مجلس وزراء الصحة العرب</p><p dir="RTL">واتحاد الصيادلة العرب</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            سبتمبر-2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Xultophy 100 units/mL + 3.6 mg/mL solution for injection.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 mL solution contains 100 units insulin degludec* and 3.6 mg liraglutide*.

*Produced in Saccharomyces cerevisiae by recombinant DNA technology.

One pre-filled pen contains 3 mL equivalent to 300 units insulin degludec and 10.8 mg liraglutide. 

One dose step contains 1 unit of insulin degludec and 0.036 mg of liraglutide. 

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection.

Clear, colourless, isotonic solution.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Xultophy is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to other oral medicinal products for the treatment of diabetes. For study results with respect to combinations, effects on glycaemic control, and the populations studied, see sections 4.4, 4.5 and 5.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><u>&nbsp;</u></p><p>Xultophy is given once daily by subcutaneous administration. Xultophy can be administered at any time of the day, preferably at the same time of the day.</p><p>&nbsp;</p><p>Xultophy is to be dosed in accordance with the individual patient&rsquo;s needs. It is recommended to optimise glycaemic control via dose adjustment based on fasting plasma glucose.</p><p>&nbsp;</p><p>Adjustment of dose may be necessary if patients undertake increased physical activity, change their usual diet or during concomitant illness.</p><p>&nbsp;</p><p>Patients who forget a dose are advised to take it upon discovery and then resume their usual once-daily dosing schedule. A minimum of 8&nbsp;hours between injections should always be ensured. This also applies when administration at the same time of the day is not possible.</p><p>&nbsp;</p><p>Xultophy is administered as dose steps. One dose step contains 1&nbsp;unit of insulin degludec and 0.036&nbsp;mg of liraglutide. The pre-filled pen can provide from 1 up to 50&nbsp;dose steps in one injection in increments of one dose step. The maximum daily dose of Xultophy is 50&nbsp;dose steps (50&nbsp;units insulin degludec and 1.8&nbsp;mg liraglutide). The dose counter on the pen shows the number of dose steps.</p><p>&nbsp;</p><p><em><u>Add-on to oral glucose-lowering medicinal products</u></em></p><p>The recommended starting dose of Xultophy is 10&nbsp;dose steps (10&nbsp;units insulin degludec and 0.36&nbsp;mg liraglutide).</p><p>&nbsp;</p><p>Xultophy can be added to existing oral antidiabetic treatment. When Xultophy is added to sulfonylurea therapy, a reduction in the dose of sulfonylurea should be considered (see section 4.4).</p><p>&nbsp;</p><p><em><u>Transfer from GLP-1 receptor agonist</u></em></p><p>Therapy with GLP-1 receptor agonists should be discontinued prior to initiation of Xultophy. When transferring from a GLP-1 receptor agonist, the recommended starting dose of Xultophy is 16&nbsp;dose steps (16&nbsp;units insulin degludec and 0.6&nbsp;mg liraglutide) (see section 5.1). The recommended starting dose should not be exceeded. If transferring from a long-acting GLP-1 receptor agonist (e.g. once-weekly dosing), the prolonged action should be considered. Treatment with Xultophy should be initiated at the moment the next dose of the long-acting GLP-1 receptor agonist would have been taken. Close glucose monitoring is recommended during the transfer and in the following weeks.</p><p>&nbsp;</p><p><em><u>Transfer from any insulin regimen that includes a basal insulin component</u></em></p><p>Therapy with other insulin regimens should be discontinued prior to initiation of Xultophy. When transferring from any other insulin therapy that includes a basal insulin component, the recommended starting dose of Xultophy is 16&nbsp;dose steps (16&nbsp;units insulin degludec and 0.6&nbsp;mg liraglutide) (see section 4.4 and 5.1). The recommended starting dose should not be exceeded, but may be reduced to avoid hypoglycaemia in selected cases. Close glucose monitoring is recommended during the transfer and in the following weeks.</p><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p><u>&nbsp;</u></p><p><em>Elderly patients (&ge;65&nbsp;years old)</em></p><p>Xultophy can be used in elderly patients. Glucose monitoring is to be intensified and the dose adjusted on an individual basis.</p><p><u>&nbsp;</u></p><p><em>Renal impairment </em></p><p>When Xultophy is used in patients with mild, moderate or severe renal impairment, glucose monitoring is to be intensified and the dose adjusted on an individual basis. Xultophy cannot be recommended for use in patients with end-stage renal disease (see sections 5.1 and 5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment </em></p><p>Xultophy can be used in patients with mild or moderate hepatic impairment. Glucose monitoring is to be intensified and the dose adjusted on an individual basis.</p><p>Due to the liraglutide component, Xultophy is not recommended for use in patients with severe hepatic impairment (see section 5.2).</p><p>&nbsp;</p><p><em>Paediatric population </em></p><p>There is no relevant use of Xultophy in the paediatric population.</p><p><em><u>&nbsp;</u></em></p><p><u>Method of administration</u></p><p><u>&nbsp;</u></p><p>Xultophy is for subcutaneous use only. Xultophy must not be administered intravenously or intramuscularly.</p><p>&nbsp;</p><p>Xultophy is administered subcutaneously by injection in the thigh, the upper arm or the abdomen. Injection sites should always be rotated within the same region in order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see sections 4.4 and 4.8). For further instructions on administration, see section 6.6.</p><p>&nbsp;</p><p>Xultophy must not be drawn from the cartridge of the pre-filled pen into a syringe (see section 4.4).</p><p>&nbsp;</p><p>Patients should be instructed to always use a new needle. The re-use of insulin pen needles increases the risk of blocked needles, which may cause under- or overdosing. In the event of blocked needles, patients must follow the instructions described in the instructions for use accompanying the package leaflet (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to either or both active substances or to any of the excipients listed in section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Xultophy should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.</p><p>&nbsp;</p><p><u>Hypoglycaemia</u></p><p>&nbsp;</p><p>Hypoglycaemia may occur if the dose of Xultophy is higher than required. Omission of a meal or unplanned strenuous physical exercise may lead to hypoglycaemia. In combination with sulfonylurea, the risk of hypoglycaemia may be lowered by a reduction in the dose of sulfonylurea. Concomitant diseases in the kidney, liver or diseases affecting the adrenal, pituitary or thyroid gland may require changes of the Xultophy dose. Patients whose blood glucose control is greatly improved (e.g. by intensified therapy) may experience a change in their usual warning symptoms of hypoglycaemia and must be advised accordingly. Usual warning symptoms (see section 4.8) of hypoglycaemia may disappear in patients with long-standing diabetes. The prolonged effect of Xultophy may delay recovery from hypoglycaemia.</p><p>&nbsp;</p><p><u>Hyperglycaemia</u></p><p><u>&nbsp;</u></p><p>Inadequate dosing and/or discontinuation of antidiabetic treatment may lead to hyperglycaemia and potentially to hyperosmolar coma. In case of discontinuation of Xultophy, ensure that instruction for initiation of alternative antidiabetic treatment is followed. Furthermore, concomitant illness, especially infections, may lead to hyperglycaemia and thereby cause an increased requirement for antidiabetic treatment. Usually, the first symptoms of hyperglycaemia develop gradually over a period of hours or days. They include thirst, increased frequency of urination, nausea, vomiting, drowsiness, flushed dry skin, dry mouth, and loss of appetite as well as acetone odour of breath.</p><p>Administration of rapid-acting insulin should be considered in situations of severe hyperglycaemia. Untreated hyperglycaemic events eventually lead to hyperosmolar coma/diabetic ketoacidosis, which is potentially lethal.</p><p>&nbsp;</p><p><u>Skin and subcutaneous tissue disorders</u></p><p><u>&nbsp;</u></p><p>Patients must be instructed to perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycaemic control following insulin injections at sites with these reactions. A sudden change in the injection site to an unaffected area has been reported to result in hypoglycaemia. Blood glucose monitoring is recommended after the change in the injection site from an affected to an unaffected area, and dose adjustment of antidiabetic medications may be considered.</p><p>&nbsp;</p><p><u>Combination of pioglitazone and insulin medicinal products</u></p><p>&nbsp;</p><p>Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin medicinal products, especially in patients with risk factors for development of cardiac failure. This should be kept in mind if treatment with the combination of pioglitazone and Xultophy is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.</p><p>&nbsp;</p><p><u>Eye disorder</u></p><p>&nbsp;</p><p>Intensification of therapy with insulin, a component of Xultophy, with abrupt improvement in glycaemic control may be associated with temporary worsening of diabetic retinopathy, while long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy.</p><p><em>&nbsp;</em></p><p><u>Antibody formation</u></p><p>&nbsp;</p><p>Administration of Xultophy may cause formation of antibodies against insulin degludec and/or liraglutide. In rare cases, the presence of such antibodies may necessitate adjustment of the Xultophy dose in order to correct a tendency to hyper- or hypoglycaemia. Very few patients developed insulin degludec specific antibodies, antibodies cross-reacting to human insulin or anti-liraglutide antibodies following treatment with Xultophy. Antibody formation has not been associated with reduced efficacy of Xultophy.</p><p>&nbsp;</p><p><u>Acute pancreatitis</u></p><p><u>&nbsp;</u></p><p>Acute pancreatitis has been observed with the use of GLP-1 receptor agonists, including liraglutide. Patients should be informed of the characteristic symptoms of acute pancreatitis. If pancreatitis is suspected, Xultophy should be discontinued; if acute pancreatitis is confirmed, Xultophy should not be restarted.</p><p>&nbsp;</p><p><u>Thyroid adverse events</u></p><p>&nbsp;</p><p>Thyroid adverse events, such as goitre have been reported in clinical trials with GLP-1 receptor agonists including liraglutide, and in particular in patients with pre-existing thyroid disease. Xultophy should therefore be used with caution in these patients.</p><p>&nbsp;</p><p><u>Inflammatory bowel disease and diabetic gastroparesis</u></p><p>&nbsp;</p><p>There is no experience with Xultophy in patients with inflammatory bowel disease and diabetic gastroparesis. Xultophy is therefore not recommended in these patients.</p><p>&nbsp;</p><p><u>Dehydration</u></p><p><u>&nbsp;</u></p><p>Signs and symptoms of dehydration, including renal impairment and acute renal failure have been reported in clinical trials with GLP-1 receptor agonists including liraglutide, a component of Xultophy. Patients treated with Xultophy should be advised of the potential risk of dehydration in relation to gastrointestinal side effects and take precautions to avoid fluid depletion.</p><p>&nbsp;</p><p><u>Avoidance of medication errors</u></p><p>&nbsp;</p><p>Patients must be instructed to always check the pen label before each injection to avoid accidental mix-ups between Xultophy and other injectable diabetes medicinal products.</p><p>&nbsp;</p><p>Patients must visually verify the dialled units on the dose counter of the pen. Therefore, the requirement for patients to self-inject is that they can read the dose counter on the pen. Patients who are blind or have poor vision must be instructed to always get help/assistance from another person who has good vision and is trained in using the insulin device.</p><p><u>&nbsp;</u></p><p>To avoid dosing errors and potential overdose, patients and healthcare professionals should never use a syringe to draw the medicinal product from the cartridge in the pre-filled pen.</p><p>&nbsp;</p><p>In the event of blocked needles, patients must follow the instructions described in the instructions for use accompanying the package leaflet (see section 6.6).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Aspiration in association with general anaesthesia or deep sedation </u></p><p>&nbsp;</p><p>Cases of pulmonary aspiration have been reported in patients receiving GLP-1 receptor agonists</p><p>undergoing general anaesthesia or deep sedation. Therefore, the increased risk of residual gastric</p><p>content due to delayed gastric emptying (see section 4.8) should be considered prior to performing procedures with general anaesthesia or deep sedation.</p><p>&nbsp;</p><p><u>Populations not studied</u></p><p>&nbsp;</p><p>Transfer to Xultophy from doses of basal insulin &lt;20 and &gt;50&nbsp;units has not been studied.</p><p>&nbsp;</p><p>There is no therapeutic experience in patients with congestive heart failure New York Heart Association (NYHA) class IV and Xultophy is therefore not recommended for use in these patients.</p><p>&nbsp;</p><p><u>Excipients</u></p><p>&nbsp;</p><p>Xultophy contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, therefore the medicinal product is essentially &lsquo;sodium-free&rsquo;.</p><p><u>&nbsp;</u></p><p><u>Traceability</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacodynamic interactions</u></p><p><u>&nbsp;</u></p><p>Interaction studies with Xultophy have not been performed.</p><p>A number of substances affect glucose metabolism and may require dose adjustment of Xultophy.</p><p>&nbsp;</p><p>The following substances may reduce the Xultophy requirement:</p><p>Antidiabetic medicinal products, monoamine oxidase inhibitors (MAOI), beta-blockers, angiotensin converting enzyme (ACE) inhibitors, salicylates, anabolic steroids and sulfonamides.</p><p>&nbsp;</p><p>The following substances may increase the Xultophy requirement:</p><p>Oral contraceptives, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormones and danazol.</p><p>&nbsp;</p><p>Beta-blockers may mask the symptoms of hypoglycaemia.</p><p>Octreotide/lanreotide may either increase or decrease the Xultophy requirement.</p><p>Alcohol may intensify or reduce the hypoglycaemic effect of Xultophy.</p><p>&nbsp;</p><p><u>Pharmacokinetic interactions</u></p><p><em><u>&nbsp;</u></em></p><p><em>In vitro</em> data suggest that the potential for pharmacokinetic drug interactions related to CYP interaction and protein binding is low for both liraglutide and insulin degludec.</p><p>&nbsp;</p><p>The small delay of gastric emptying with liraglutide may influence absorption of concomitantly administered oral medicinal products. Interaction studies did not show any clinically relevant delay of absorption.</p><p>&nbsp;</p><p><em><u>Warfarin and other coumarin derivatives</u></em></p><p>No interaction study has been performed. A clinically relevant interaction with active substances with poor solubility or with narrow therapeutic index such as warfarin cannot be excluded. Upon initiation of Xultophy treatment in patients on warfarin or other coumarin derivatives more frequent monitoring of INR (International Normalised Ratio) is recommended.</p><p><em>&nbsp;</em></p><p><em><u>Paracetamol </u></em></p><p>Liraglutide did not change the overall exposure of paracetamol following a single dose of 1,000&nbsp;mg. Paracetamol C<sub>max</sub> was decreased by 31% and median t<sub>max</sub> was delayed up to 15&nbsp;min. No dose adjustment for concomitant use of paracetamol is required.</p><p><em>&nbsp;</em></p><p><em><u>Atorvastatin</u></em></p><p>Liraglutide did not change the overall exposure of atorvastatin to a clinical relevant degree following single dose administration of atorvastatin 40&nbsp;mg. Therefore, no dose adjustment of atorvastatin is required when given with liraglutide. Atorvastatin C<sub>max</sub> was decreased by 38% and median t<sub>max</sub> was delayed from 1&nbsp;h to 3&nbsp;h with liraglutide.</p><p><em>&nbsp;</em></p><p><em><u>Griseofulvin</u></em></p><p>Liraglutide did not change the overall exposure of griseofulvin following administration of a single dose of griseofulvin 500&nbsp;mg. Griseofulvin C<sub>max</sub> increased by 37% while median t<sub>max</sub> did not change. Dose adjustments of griseofulvin and other compounds with low solubility and high permeability are not required.</p><p>&nbsp;</p><p><em><u>Digoxin</u></em></p><p>A single dose administration of digoxin 1&nbsp;mg with liraglutide resulted in a reduction of digoxin AUC by 16%; C<sub>max</sub> decreased by 31%. Digoxin median time to maximum concentration (t<sub>max</sub>) was delayed from 1&nbsp;h to 1.5&nbsp;h. No dose adjustment of digoxin is required based on these results.</p><p><em>&nbsp;</em></p><p><em><u>Lisinopril</u></em></p><p>A single dose administration of lisinopril 20&nbsp;mg with liraglutide resulted in a reduction of lisinopril AUC by 15%; C<sub>max</sub> decreased by 27%. Lisinopril median t<sub>max</sub> was delayed from 6&nbsp;h to 8&nbsp;h with liraglutide. No dose adjustment of lisinopril is required based on these results.</p><p><em>&nbsp;</em></p><p><em><u>Oral contraceptives</u></em></p><p>Liraglutide lowered ethinylestradiol and levonorgestrel C<sub>max</sub> by 12 and 13%, respectively, following administration of a single dose of an oral contraceptive product. T<sub>max</sub> was delayed by 1.5&nbsp;h with liraglutide for both compounds. There was no clinically relevant effect on the overall exposure of either ethinylestradiol or levonorgestrel. The contraceptive effect is therefore anticipated to be unaffected when co-administered with liraglutide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><u>&nbsp;</u></p><p>There is no clinical experience with the use of Xultophy, insulin degludec or liraglutide in pregnant women. If a patient wishes to become pregnant, or pregnancy occurs, treatment with Xultophy should be discontinued.</p><p>&nbsp;</p><p>Animal reproduction studies with insulin degludec have not revealed any differences between insulin degludec and human insulin regarding embryotoxicity and teratogenicity. Animal studies with liraglutide have shown reproductive toxicity, see section 5.3. The potential risk for humans is unknown.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p><u>&nbsp;</u></p><p>There is no clinical experience with the use of Xultophy during breast-feeding. It is not known whether insulin degludec or liraglutide is excreted in human milk. Because of lack of experience, Xultophy should not be used during breast-feeding.</p><p>In rats, insulin degludec was secreted in milk; the concentration in milk was lower than in plasma. Animal studies have shown that the transfer of liraglutide and metabolites of close structural relationship into milk was low. Non-clinical studies with liraglutide have shown a treatment-related reduction of neonatal growth in suckling rat pups (see section 5.3).</p><p><em>&nbsp;</em></p><p><u>Fertility</u></p><p><em><u>&nbsp;</u></em></p><p>There is no clinical experience with Xultophy in relation to fertility.</p><p>Animal reproduction studies with insulin degludec have not revealed any adverse effects on fertility. Apart from a slight decrease in the number of live implants, animal studies with liraglutide did not indicate harmful effects with respect to fertility.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The patient&rsquo;s ability to concentrate and react may be impaired as a result of hypoglycaemia. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or using machines).</p><p>&nbsp;</p><p>Patients must be advised to take precautions to avoid hypoglycaemia while driving. This is particularly important in those who have reduced or absent awareness of the warning signs of hypoglycaemia or have frequent episodes of hypoglycaemia. The advisability of driving should be considered in these circumstances.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile </u></p><p>&nbsp;</p><p>The Xultophy clinical development programme included approximately 1,900&nbsp;patients treated with Xultophy.</p><p>&nbsp;</p><p>The most frequently reported adverse reactions during treatment with Xultophy were hypoglycaemia and gastrointestinal adverse reactions (see section &lsquo;Description of selected adverse reactions&rsquo; below).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>Adverse reactions associated with Xultophy are given below, listed by system organ class and frequency. Frequency categories are defined as: Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000) and not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>Table 1 Adverse reactions reported in phase 3 controlled studies</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td></tr><tr><td style="vertical-align:top"><p>Unknown</p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Hypoglycaemia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Decreased appetite</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Dehydration</p></td></tr><tr><td rowspan="2"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dizziness</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Dysgeusia</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Nausea, diarrhoea, vomiting, constipation, dyspepsia, gastritis, abdominal pain, gastroesophageal reflux disease, abdominal distension</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Eructation, flatulence</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Unknown</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Acute pancreatitis, hemorrhagic and necrotizing pancreatitis sometimes resulting in death</p></td></tr><tr><td style="vertical-align:top"><p>Intestinal Obstruction</p></td></tr><tr><td style="vertical-align:top"><p>Delayed gastric emptying</p></td></tr><tr><td rowspan="2"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cholelithiasis</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cholecystitis</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rash</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Lipodystrophy acquired</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Cutaneous amyloidosis<sup>&dagger;</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration site condition</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Injection site reaction</p></td></tr><tr><td style="vertical-align:top"><p>Unknown</p></td><td style="vertical-align:top"><p>Peripheral oedema</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Investigation</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Increased lipase</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Increased amylase</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Increased heart rate</p></td></tr></tbody></table><p>&dagger; ADR from postmarketing sources.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions </u></p><p>&nbsp;</p><p><em><u>Hypoglycaemia</u></em></p><p>Hypoglycaemia may occur if the Xultophy dose is higher than required. Severe hypoglycaemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or even death. The symptoms of hypoglycaemia usually occur suddenly. They may include cold sweats, cool pale skin, fatigue, nervousness or tremor, anxiousness, unusual tiredness or weakness, confusion, difficulty in concentration, drowsiness, excessive hunger, vision changes, headache, nausea and palpitation. For frequencies of hypoglycaemia, please see section 5.1.</p><p><u>&nbsp;</u></p><p><em><u>Allergic reactions</u></em></p><p>Allergic reactions (manifested with signs and symptoms such as urticaria (0.3% of patients treated with Xultophy), rash (0.7%), pruritus (0.5%) and/or swelling of the face (0.2%)) have been reported for Xultophy. Few cases of anaphylactic reactions with additional symptoms such as hypotension, palpitations, dyspnoea, and oedema have been reported during marketed use of liraglutide. Anaphylactic reactions may potentially be life threatening.</p><p>&nbsp;</p><p><em><u>Gastrointestinal adverse reactions</u></em></p><p>Gastrointestinal adverse reactions may occur more frequently at the beginning of Xultophy therapy and usually diminish within a few days or weeks on continued treatment. Nausea was reported in 7.8% of patients and was transient in nature for most patients. The proportion of patients reporting nausea per week at any point during treatment was below 4%. Diarrhoea and vomiting were reported in 7.5% and 3.9% of patients, respectively. The frequency of nausea and diarrhoea was &lsquo;Common&rsquo; for Xultophy and &lsquo;Very common&rsquo; for liraglutide. In addition, constipation, dyspepsia, gastritis, abdominal pain, gastroesophageal reflux disease, abdominal distension, eructation, flatulence and decreased appetite have been reported in up to 3.6% of patients treated with Xultophy.</p><p><strong>&nbsp;</strong></p><p><em><u>Injection site reactions</u></em></p><p>Injection site reactions (including injection site haematoma, pain, haemmorrhage, erythema, nodules, swelling, discolouration, pruritus, warmth and injection site mass) have been reported in 2.6% of patients treated with Xultophy. These reactions were usually mild and transitory and they normally disappear during continued treatment.</p><p><strong>&nbsp;</strong></p><p><em><u>Skin and subcutaneous tissue disorders</u></em></p><p>Lipodystrophy (including lipohypertrophy, lipoatrophy) and cutaneous amyloidosis may occur at the injection site and delay local insulin absorption. Continuous rotation of the injection site within the given injection area may help to reduce or prevent these reactions (see section 4.4).</p><p>&nbsp;</p><p><em>Increased heart rate </em></p><p>Mean increase in heart rate from baseline of 2 to 3&nbsp;beats per minute has been observed in clinical trials with Xultophy. In the LEADER trial, no long-term clinical impact of increased heart rate on the risk of cardiovascular events was observed with liraglutide (a component of Xultophy) (see section 5.1).</p><p>&nbsp;</p><p>Please report adverse events to:</p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:90.05pt;margin-top:12.8pt;width:431.25pt;height:113.85pt;
  z-index:-15728640;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".96pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-left:22.85pt;text-indent:-18.05pt;
     line-height:12.85pt;mso-line-height-rule:exactly;mso-list:l2 level1 lfo3;
     tab-stops:22.85pt 22.9pt'><![if !supportLists]><span lang=EN-US
     style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
     Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><span lang=EN-US>The
     National Pharmacovigilance Centre<span style='letter-spacing:-1.0pt'> </span>(NPC):<o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-top:.15pt'><span lang=EN-US><o:p>&nbsp;</o:p></span></p>
     <p class=MsoBodyText style='margin-left:4.85pt;tab-stops:22.85pt'><span
     lang=EN-US style='font-family:Symbol'>-</span><span lang=EN-US><span
     style='mso-tab-count:1'>    </span>Fax:<span style='letter-spacing:-.1pt'>
     </span>+966-11-205-7662<o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-top:1.85pt;margin-right:0in;margin-bottom:
     0in;margin-left:22.85pt;margin-bottom:.0001pt;text-indent:-18.05pt;
     mso-list:l1 level1 lfo2;tab-stops:22.8pt 22.9pt'><![if !supportLists]><span
     lang=EN-US style='font-family:Symbol;mso-fareast-font-family:Symbol;
     mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>-<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><span lang=EN-US>SFDA Call Center:<span style='letter-spacing:
     -.5pt'> </span>19999</span><span lang=EN-US style='font-family:Symbol'><o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-top:1.9pt;margin-right:0in;margin-bottom:
     0in;margin-left:22.85pt;margin-bottom:.0001pt;text-indent:-18.05pt;
     mso-list:l1 level1 lfo2;tab-stops:22.8pt 22.9pt'><![if !supportLists]><span
     lang=EN-US style='font-family:Symbol;mso-fareast-font-family:Symbol;
     mso-bidi-font-family:Symbol;color:#0462C1'><span style='mso-list:Ignore'>-<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><span lang=EN-US>E-mail:<span style='color:#0462C1;
     letter-spacing:.1pt'> </span><a href="mailto:npc.drug@sfda.gov.sa"><span
     style='color:#0462C1'>npc.drug@sfda.gov.sa<span style='letter-spacing:
     .4pt'> </span></span></a></span><span lang=EN-US style='font-family:Symbol;
     color:#0462C1'><o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-top:1.65pt;margin-right:0in;margin-bottom:
     0in;margin-left:22.85pt;margin-bottom:.0001pt;text-indent:-18.05pt;
     mso-list:l1 level1 lfo2;tab-stops:22.85pt 22.9pt'><![if !supportLists]><span
     lang=EN-US style='font-family:Symbol;mso-fareast-font-family:Symbol;
     mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>-<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><span lang=EN-US>Website:<span style='color:#0462C1;
     letter-spacing:-.15pt'> </span><a href="https://ade.sfda.gov.sa/"><span
     style='color:#0462C1'>https://ade.sfda.gov.sa/</span></a></span><span
     lang=EN-US style='font-family:Symbol'><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="_x0000_s1027" type="#_x0000_t202" style='position:absolute;margin-left:90.05pt;
  margin-top:9.85pt;width:431.25pt;height:16.35pt;z-index:-15728128;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".96pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-left:22.85pt;text-indent:-18.05pt;
     line-height:12.95pt;mso-line-height-rule:exactly;mso-list:l0 level1 lfo1;
     tab-stops:22.85pt 22.9pt'><![if !supportLists]><span lang=EN-US
     style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
     Symbol'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><i style='mso-bidi-font-style:
     normal'><span lang=EN-US>Please contact the relevant competent authority.<o:p></o:p></span></i></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>The National Pharmacovigilance Centre (NPC):</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Limited data are available with regard to overdose of Xultophy.</p><p>&nbsp;</p><p>Hypoglycaemia may develop if a patient is dosed with more Xultophy than required:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mild hypoglycaemic episodes can be treated by oral administration of glucose or other products containing sugar. It is therefore recommended that the patient always carries sugar-containing products</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe hypoglycaemic episodes, where the patient is not able to treat himself, can be treated with glucagon given intramuscularly, subcutaneously or intranasally by a trained person, or with glucose given intravenously by a healthcare professional. Glucose must be given intravenously if the patient does not respond to glucagon within 10 to 15&nbsp;minutes. Upon regaining consciousness, administration of oral carbohydrates is recommended for the patient in order to prevent a relapse.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in diabetes. Insulins and analogues for injection, long-acting. ATC code: A10AE56</p><p><em>&nbsp;</em></p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Xultophy is a combination product consisting of insulin degludec and liraglutide having complementary mechanisms of action to improve glycaemic control.</p><p><em>&nbsp;</em></p><p>Insulin degludec is a basal insulin that forms soluble multi-hexamers upon subcutaneous injection, resulting in a depot from which insulin degludec is continuously and slowly absorbed into the circulation leading to a flat and stable glucose-lowering effect of insulin degludec with a low day-to-day variability in insulin action.</p><p>&nbsp;</p><p>Insulin degludec binds specifically to the human insulin receptor and results in the same pharmacological effects as human insulin.</p><p>&nbsp;</p><p>The blood glucose-lowering effect of insulin degludec is due to the facilitated uptake of glucose following the binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.</p><p><u>&nbsp;</u></p><p>Liraglutide is a Glucagon-Like Peptide-1 (GLP-1) analogue with 97% sequence homology to human GLP-1 that binds to and activates the GLP-1 receptor (GLP-1R). Following subcutaneous administration, the protracted action profile is based on three mechanisms: self-association, which results in slow absorption; binding to albumin; and higher enzymatic stability towards the dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidase (NEP) enzymes, resulting in a long plasma half-life.</p><p>&nbsp;</p><p>Liraglutide action is mediated via a specific interaction with GLP-1 receptors and improves glycaemic control by lowering fasting and postprandial blood glucose. Liraglutide stimulates insulin secretion and lowers inappropriately high glucagon secretion in a glucose-dependent manner. Thus, when blood glucose is high, insulin secretion is stimulated and glucagon secretion is inhibited. Conversely, during hypoglycaemia liraglutide diminishes insulin secretion and does not impair glucagon secretion. The mechanism of blood glucose-lowering also involves a minor delay in gastric emptying.</p><p>&nbsp;</p><p>Liraglutide reduces body weight and body fat mass through mechanisms involving reduced hunger and lowered energy intake.</p><p>&nbsp;</p><p>GLP-1 is a physiological regulator of appetite and food intake, but the exact mechanism of action is not entirely clear. In animal studies, peripheral administration of liraglutide led to uptake in specific brain regions involved in regulation of appetite, where liraglutide, via specific activation of the GLP-1R, increased key satiety and decreased key hunger signals, thereby leading to lower body weight.</p><p>&nbsp;</p><p>GLP-1 receptors are also expressed in specific locations in the heart, vasculature, immune system, and kidneys. In mouse models of atherosclerosis, liraglutide prevented aortic plaque progression and reduced inflammation in the plaque. In addition, liraglutide had a beneficial effect on plasma lipids. Liraglutide did not reduce the plaque size of already established plaques.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p><em>&nbsp;</em></p><p>Xultophy has a stable pharmacodynamic profile with a duration of action reflecting the combination of the individual action profiles of insulin degludec and liraglutide that allows for administration of Xultophy once daily at any time of the day with or without meals. Xultophy improves glycaemic control through the sustained lowering of fasting plasma glucose levels and postprandial glucose levels after all meals.</p><p>&nbsp;</p><p>Postprandial glucose reduction was confirmed in a 4&nbsp;hour standardised meal test substudy in patients uncontrolled on metformin alone or in combination with pioglitazone. Xultophy decreased the postprandial plasma glucose excursion (mean over 4&nbsp;hours) significantly more than insulin degludec. The results were similar for Xultophy and liraglutide.</p><p><em><u>&nbsp;</u></em></p><p><u>Clinical<em> </em>efficacy and safety</u></p><p>&nbsp;</p><p>The safety and efficacy of Xultophy were evaluated in seven randomised, controlled, parallel group phase 3 trials in different populations of subjects with type 2 diabetes defined by previous antidiabetes treatment. Comparator treatments comprised basal insulin, GLP-1 RA therapy, placebo and a basal bolus regimen. The trials were of 26 weeks duration randomising between 199 and 833&nbsp;patients to Xultophy. One study was further extended to 52 weeks. In all trials, the starting dose was given according to label and a twice-weekly titration regimen for Xultophy was used (see Table 2). The same titration algorithm was applied for basal insulin comparators. In six studies, Xultophy produced clinically and statistically significant improvements in glycaemic control versus comparators as measured by glycated haemaglobin A<sub>1c</sub> (HbA<sub>1c</sub>), whereas one study demonstrated a similar reduction of HbA<sub>1c</sub> in both treatment arms.</p><p>&nbsp;</p><p>Table 2 Titration of Xultophy</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2"><p><strong>Pre-breakfast plasma glucose*</strong></p></td><td><p><strong>Dose adjustment (twice weekly)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>mmol/L</p></td><td style="vertical-align:bottom"><p>mg/dL</p></td><td style="vertical-align:bottom"><p>Xultophy (dose steps)</p></td></tr><tr><td><p>&lt;4.0</p></td><td><p>&lt;72</p></td><td><p>-2</p></td></tr><tr><td><p>4.0&ndash;5.0</p></td><td><p>72&ndash;90</p></td><td><p>0</p></td></tr><tr><td><p>&gt;5.0</p></td><td><p>&gt;90</p></td><td><p>+2</p></td></tr></tbody></table><p>*Self-measured plasma glucose. In the trial investigating Xultophy as add on to sulfonylurea the target was 4.0-6.0 mmol/L</p><p>&nbsp;</p><p><em>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>Glycaemic control</p><p>&nbsp;</p><p><em><u>Add-on to oral glucose-lowering medicinal products </u></em></p><p>Adding Xultophy to metformin alone or in combination with pioglitazone in a 26-week randomised, controlled, open-label trial resulted in 60.4% of patients treated with Xultophy reaching a target of HbA<sub>1c</sub> &lt;7% without confirmed hypoglycaemic episodes after 26&nbsp;weeks of treatment. The proportion was significantly larger than observed with insulin degludec (40.9%, odds ratio 2.28, p &lt;0.0001) and similar to that observed with liraglutide (57.7%, odds ratio 1.13, p=0.3184). The key results of the trial are listed in Figure 1 and Table 3.</p><p>&nbsp;</p><p>Rates of confirmed hypoglycaemia were lower with Xultophy than with insulin degludec irrespective of the glycaemic control, see Figure 1. The rate per patient year of exposure (percentage of patients) of severe hypoglycaemia defined as an episode requiring assistance of another person was 0.01 (2&nbsp;patients out of 825) for Xultophy, 0.01 (2&nbsp;patients out of 412) for insulin degludec and 0.00 (0&nbsp;patients out of 412) for liraglutide. The rate of nocturnal hypoglycaemic events was similar with Xultophy and insulin degludec treatment.</p><p>&nbsp;</p><p>Patients treated with Xultophy overall experienced less gastrointestinal side effects than patients treated with liraglutide. This might be due to the slower increase in the dose of the liraglutide component during treatment initiation when using Xultophy as compared to using liraglutide alone.</p><p>&nbsp;</p><p>The efficacy and safety of Xultophy were sustained up to 52&nbsp;weeks of treatment. The reduction in HbA<sub>1c</sub> from baseline to 52&nbsp;weeks was 1.84% with Xultophy with an estimated treatment difference of -0.65% compared to liraglutide (p&lt;0.0001) and -0.46% compared to insulin degludec (p&lt;0.0001). Body weight was reduced by 0.4&nbsp;kg with an estimated treatment difference between Xultophy and insulin degludec of -2.80&nbsp;kg (p&lt;0.0001), and the rate of confirmed hypoglycaemia remained 1.8&nbsp;events per patient year of exposure maintaining a significant reduction in overall risk of confirmed hypoglycaemia compared to insulin degludec.</p><p><img alt="" width="707" height="239" src="data:image/png;base64,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" /></p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p><br /><!--[if gte mso 9]><xml>
   <o:OLEObject Type="Embed" ProgID="Word.Document.12" ShapeID="_x0000_i1025"
    DrawAspect="Content" ObjectID="_1782814242">
   </o:OLEObject>
  </xml><![endif]--></p></td><td style="vertical-align:top"><p><br /><strong><!--[if gte mso 9]><xml>
   <o:OLEObject Type="Embed" ProgID="Word.Document.12" ShapeID="_x0000_i1026"
    DrawAspect="Content" ObjectID="_1782814243">
   </o:OLEObject>
  </xml><![endif]--></strong></p></td></tr></tbody></table><p>IDegLira=Xultophy, IDeg=insulin degludec, Lira=liraglutide, obs. rate=observed rate, PYE=patient year of exposure</p><p><strong>&nbsp;</strong></p><p><strong>Figure 1 Mean HbA<sub>1c</sub>&nbsp;(%) by treatment week (left) and r</strong><strong>ate of confirmed hypoglycaemia per patient year of exposure vs mean HbA<sub>1c</sub>&nbsp;(%) (right) </strong><strong>in patients with type 2 diabetes mellitus inadequately controlled on metformin alone or in combination with pioglitazone</strong></p><p>&nbsp;</p><p>Xultophy as add-on to sulfonylurea alone or in combination with metformin were studied in a 26-week randomised, placebo-controlled, double-blind trial. The key results of the trial are listed in Figure 2 and Table 3.</p><p><img alt="" width="408" height="199" src="data:image/png;base64,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" /></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><br /><!--[if gte mso 9]><xml>
   <o:OLEObject Type="Embed" ProgID="Word.Document.12" ShapeID="_x0000_i1027"
    DrawAspect="Content" ObjectID="_1782814244">
   </o:OLEObject>
  </xml><![endif]--></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>IDegLira=Xultophy</p><p><strong>&nbsp;</strong></p><p><strong>Figure 2 Mean HbA<sub>1c</sub>&nbsp;(%) by treatment week in patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or in combination with metformin </strong></p><p>&nbsp;</p><p>The rate per patient year of exposure (percentage of patients) of severe hypoglycaemia was 0.02 (2 patients out of 288) for Xultophy and 0.00 (0&nbsp;patients out of 146) for placebo.</p><p>&nbsp;</p><p>Table 3 Results at 26-weeks &ndash; Add on to oral glucose-lowering medicinal products</p><table border="1" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td><p>&nbsp;</p></td><td colspan="3"><p><strong>Add on to metformin &plusmn; pioglitazone </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Add on to sulfonylurea &plusmn; metformin</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>Xultophy</strong></p></td><td><p><strong>Insulin degludec</strong></p></td><td><p><strong>Liraglutide</strong></p></td><td style="vertical-align:top"><p><strong>Xultophy</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td><p><strong>N</strong></p></td><td><p>833</p></td><td><p>413</p></td><td><p>414</p></td><td style="vertical-align:top"><p>289</p></td><td style="vertical-align:top"><p>146</p></td></tr><tr><td><p><strong>HbA<sub>1c</sub>&nbsp;(%)</strong></p><p>Baseline&rarr;End of trial</p><p>Mean change</p><p><em>Estimated difference</em></p></td><td><p>&nbsp;</p><p>8.3&rarr;6.4</p><p>-1.91</p><p><em>&nbsp;</em></p></td><td><p>&nbsp;</p><p>8.3&rarr;6.9</p><p>-1.44</p><p><em>-0.47<sup>AB</sup>[-0.58; -0.36]</em></p></td><td><p>&nbsp;</p><p>8.3&rarr;7.0</p><p>-1.28</p><p><em>-0.64<sup>AB</sup>[-0.75; -0.53]</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>7.9&rarr;6.4</p><p>-1.45</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>7.9&rarr;7.4</p><p>-0.46</p><p><em>-1.02<sup>AB</sup>[-1.18; -0.87] </em></p></td></tr><tr><td><p><strong>Patients (%) achieving HbA<sub>1c</sub> &lt;7%</strong><br />All patients</p><p><em>Estimated odds ratio</em></p></td><td><p>&nbsp;</p><p><br />80.6</p><p>&nbsp;</p></td><td><p>&nbsp;</p><p><br />65.1</p><p><em>2.38<sup>B</sup> [1.78;</em> <em>3.18]</em></p></td><td><p>&nbsp;</p><p><br />60.4</p><p><em>3.26<sup>B</sup> [2.45; 4.33]</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><br />79.2</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><br />28.8</p><p><em>11.95<sup>B</sup> [7.22; 19.77] </em></p></td></tr><tr><td><p><strong>Patients (%) achieving HbA<sub>1c</sub> </strong><strong>&pound;</strong><strong>6.5%</strong><br />All patients</p><p><em>Estimated odds ratio</em></p></td><td><p>&nbsp;</p><p><br />69.7</p><p>&nbsp;</p></td><td><p>&nbsp;</p><p><br />47.5</p><p><em>2.82<sup>B</sup> [2.17;</em> <em>3.67]</em></p></td><td><p>&nbsp;</p><p><br />41.1</p><p><em>3.98<sup>B</sup> [3.05; 5.18]</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><br />64.0</p><p>&nbsp;</p></td><td style="vertical-align:top"><p><br />&nbsp;</p><p>12.3</p><p><em>16.36<sup>B</sup> [9.05; 29.56] </em></p></td></tr><tr><td><p><strong>Rate of confirmed hypoglycaemia* per patient year of exposure (percentage of patients)</strong></p><p><em>Estimated ratio</em></p></td><td><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>1.80 (31.9%)</p><p>&nbsp;</p></td><td><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>2.57 (38.6%)</p><p><em>0.68<sup>AC</sup> [0.53; 0.87]</em></p></td><td><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>0.22 (6.8%)</p><p><em>7.61<sup>B</sup> [5.17; 11.21]</em></p></td><td><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>3.52 (41.7%)</p></td><td><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>1.35 (17.1%)</p><p><em>3.74<sup>B</sup> [2.28; 6.13] </em></p></td></tr><tr><td><p><strong>Body Weight (kg)</strong></p><p>Baseline&rarr;End of trial<br />Mean change</p><p><em>Estimated difference</em></p></td><td><p>&nbsp;</p><p>87.2&rarr;86.7</p><p>-0.5</p><p>&nbsp;</p></td><td><p>&nbsp;</p><p>87.4&rarr;89.0</p><p>1.6</p><p><em>-2.22<sup>AB</sup> [-2.64; -1.80]</em></p></td><td><p>&nbsp;</p><p>87.4&rarr;84.4</p><p>-3.0</p><p><em>2.44<sup>B</sup> [2.02; 2.86]</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>87.2&rarr;87.7</p><p>0.5</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>89.3&rarr;88.3</p><p>-1.0</p><p><em>1.48<sup>B</sup> [0.90; 2.06]</em></p></td></tr><tr><td><p><strong>FPG (mmol/L)</strong></p><p>Baseline&rarr;End of trial</p><p>Mean change</p><p><em>Estimated difference</em></p></td><td><p>&nbsp;</p><p>9.2&rarr;5.6</p><p>-3.62</p><p>&nbsp;</p></td><td><p>&nbsp;</p><p>9.4&rarr;5.8</p><p>-3.61</p><p><em>-0.17 [-0.41; 0.07]</em></p></td><td><p>&nbsp;</p><p>9.0&rarr;7.3</p><p>-1.75</p><p><em>-1.76<sup>B</sup> [-2.0; -1.53]</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>9.1&rarr;6.5</p><p>-2.60</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>9.1&rarr;8.8</p><p>-0.31</p><p><em>-2.30<sup>B</sup> [-2.72; -1.89]</em></p></td></tr><tr><td><p><strong>Dose End of trial</strong></p><p>Insulin degludec (units)<br />Liraglutide (mg)</p><p><em>Estimated difference, insulin degludec dose</em></p></td><td><p>&nbsp;</p><p>38</p><p>1.4</p><p>&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p><p>53</p><p>-</p><p><em>-14.90<sup>AB</sup> [-17.14;<br />&nbsp;-12.66]</em></p></td><td><p>&nbsp;</p><p>-</p><p>1.8</p><p>&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p><p>28</p><p>1.0</p><p>&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p><p>-</p><p>-</p><p><em>-</em></p><p>&nbsp;</p></td></tr></tbody></table><p>Baseline, End of trial and change values are observed Last observation carried forward. The 95% confidence interval is stated in &lsquo;[]&rsquo;</p><p>*Confirmed hypoglycaemia defined as severe hypoglycaemia (episode requiring assistance of another person) and/or minor hypoglycaemia (plasma glucose &lt;3.1&nbsp;mmol/L irrespective of symptoms)</p><p><sup>A</sup> Endpoints with confirmed superiority of Xultophy vs comparator</p><p><sup>B</sup> p&lt;0.0001</p><p><sup>C</sup> p&lt;0.05</p><p>&nbsp;</p><p>In an open label trial comparing the efficacy and safety of Xultophy and insulin glargine 100&nbsp;units/mL, both as add-on to SGLT2i &plusmn; OAD, Xultophy was superior to insulin glargine in reducing mean HbA<sub>1c</sub> after 26&nbsp;weeks by 1.9% (from 8.2% to 6.3%) versus 1.7% (from 8.4% to 6.7%) with an estimated treatment difference of -0.36% [-0.50; -0.21]. Compared to baseline, Xultophy resulted in an unchanged mean body weight compared to a mean weight increase of 2.0&nbsp;kg for patients treated with insulin glargine (estimated treatment difference -1.92&nbsp;kg [95% CI: -2.64; -1.19]). The percentage of patients experiencing severe or blood-glucose confirmed symptomatic hypoglycaemia was 12.9% in the Xultophy group and 19.5% in the insulin glargine group (estimated treatment ratio 0.42 [95% CI: 0.23; 0.75]). The mean daily insulin dose at end of trial was 36&nbsp;units for patients treated with Xultophy and 54&nbsp;units for patients treated with insulin glargine.</p><p>&nbsp;</p><p><em><u>Transfer from GLP-1 receptor agonist therapy</u></em></p><p>Transfer from GLP-1 receptor agonist to Xultophy compared to unchanged GLP-1 receptor agonist therapy (dosed according to label) were studied in a 26-weeks randomised, open-label trial in patients with type 2 diabetes mellitus inadequately controlled on a GLP-1 receptor agonist and metformin alone (74.2%) or in combination with pioglitazone (2.5%), sulfonylurea (21.2%) or both (2.1%).</p><p>The key results of the trial are listed in Figure 3 and Table 4.</p><p><strong>&nbsp;</strong><img alt="" width="355" height="189" src="data:image/png;base64,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" /></p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p><br /><strong><!--[if gte mso 9]><xml>
   <o:OLEObject Type="Embed" ProgID="Word.Document.12" ShapeID="_x0000_i1028"
    DrawAspect="Content" ObjectID="_1782814245">
   </o:OLEObject>
  </xml><![endif]--></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>IDegLira=Xultophy, GLP-1 RA=GLP-1 receptor agonist</p><p><strong>&nbsp;</strong></p><p><strong>Figure 3 Mean HbA<sub>1c</sub>&nbsp;(%) by treatment week in patients with type 2 diabetes mellitus inadequately controlled on GLP-1 receptor agonists</strong></p><p>&nbsp;</p><p>The rate per patient year of exposure (percentage of patients) of severe hypoglycaemia was 0.01 (1&nbsp;patient out of 291) for Xultophy and 0.00 (0 patients out of 199) for GLP-1 receptor agonists.</p><p>&nbsp;</p><p><strong>Table 4 Results at 26-weeks &ndash; Transfer from GLP-1 receptor agonists</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:520px"><tbody><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Transfer from GLP-1 receptor agonist</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Xultophy</strong></p></td><td style="vertical-align:top"><p><strong>GLP-1 receptor agonist</strong></p></td></tr><tr><td><p><strong>N</strong></p></td><td style="vertical-align:top"><p>292</p></td><td style="vertical-align:top"><p>146</p></td></tr><tr><td><p><strong>HbA<sub>1c</sub>&nbsp;(%)</strong></p><p>Baseline&rarr;End of trial</p><p>Mean change</p><p><em>Estimated difference</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>7.8&rarr;6.4</p><p>-1.3</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>7.7&rarr;7.4</p><p>-0.3</p><p><em>-0.94<sup>AB</sup>[-1.11; -0.78] </em></p></td></tr><tr><td><p><strong>Patients (%) achieving HbA<sub>1c</sub> &lt;7%</strong><br />All patients</p><p><em>Estimated odds ratio</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>75.3</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>35.6</p><p><em>6.84<sup>B</sup> [4.28; 10.94] </em></p></td></tr><tr><td><p><strong>Patients (%) achieving HbA<sub>1c</sub> </strong><strong>&pound;</strong><strong>6.5%</strong><br />All patients</p><p><em>Estimated odds ratio</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>63.0</p><p>&nbsp;</p></td><td style="vertical-align:top"><p><br />22.6</p><p><em>7.53<sup>B</sup> [4.58; 12.38] </em></p></td></tr><tr><td><p><strong>Rate of confirmed hypoglycaemia* per patient year of exposure (percentage of patients)</strong></p><p><em>Estimated ratio</em></p></td><td><p>&nbsp;</p><p>&nbsp;</p><p>2.82 (32.0%)</p><p>&nbsp;</p></td><td><p>&nbsp;</p><p>&nbsp;</p><p>0.12 (2.8%)</p><p><em>25.36<sup>B</sup> [10.63; 60.51] </em></p></td></tr><tr><td><p><strong>Body Weight (kg)</strong></p><p>Baseline&rarr;End of trial<br />Mean change</p><p><em>Estimated difference</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>95.6&rarr;97.5</p><p>2.0</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>95.5&rarr;94.7</p><p>-0.8</p><p><em>2.89<sup>B</sup> [2.17; 3.62]</em></p></td></tr><tr><td><p><strong>FPG (mmol/L)</strong></p><p>Baseline&rarr;End of trial</p><p>Mean change</p><p><em>Estimated difference</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>9.0&rarr;6.0</p><p>-2.98</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>9.4&rarr;8.8</p><p>-0.60</p><p><em>-2.64<sup>B</sup> [-3.03; -2.25]</em></p></td></tr><tr><td><p><strong>Dose End of trial</strong></p><p>Insulin degludec (units)<br />Liraglutide (mg)</p><p><em>Estimated difference, insulin degludec dose</em></p></td><td><p>&nbsp;</p><p>43</p><p>1.6</p><p>&nbsp;</p><p>&nbsp;</p></td><td><p><em>GLP-1 receptor agonist dose was to be continued unchanged from baseline</em></p></td></tr></tbody></table><p>Baseline, End of trial and change values are observed Last observation carried forward. The 95% confidence interval is stated in &lsquo;[]&rsquo;</p><p>*Confirmed hypoglycaemia defined as severe hypoglycaemia (episode requiring assistance of another person) and/or minor hypoglycaemia (plasma glucose &lt;3.1&nbsp;mmol/L irrespective of symptoms)</p><p><sup>A</sup> Endpoints with confirmed superiority of Xultophy vs comparator</p><p><sup>B</sup> p&lt;0.001</p><p>&nbsp;</p><p><em><u>Transfer from basal insulin therapies</u></em></p><p>Transfer of patients from insulin glargine (100&nbsp;units/mL) to Xultophy or intensification of insulin glargine in patients inadequately controlled on insulin glargine (20-50 units) and metformin were studied in a 26 week trial. The maximum allowed dose in the trial was 50 dose steps for Xultophy whereas there was no maximum dose for insulin glargine. 54.3% of patients treated with Xultophy reached the HbA<sub>1c</sub> target of &lt;7% without confirmed hypoglycaemic episodes compared to 29.4% of patients treated with insulin glargine (odds ratio 3.24, p&lt;0.001).</p><p>&nbsp;</p><p>The key results of the trial are listed in Figure 4 and Table 5.</p><p>&nbsp;</p><p><img alt="" width="403" height="181" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZMAAAC1CAYAAACanhL+AAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAAEv4SURBVHhe7Z2Je5XVtf/5A+4/QK8MIaj3d+vtINo6tebW5+LUqrXyODYi1uJYpxrFARHCGEVBEEGi1AFxiKI4AIoDWmWIFgdEFFERo0IFMShqhPV7Pzvne9g5nJOcjBxO1vfJyt7vHtbZ7x7W2tO7dw9zOBwOh6OdcGXicDgcjnbDlYnD4XA42g1XJg6Hw+FoN1yZOBwOh6PdcGXicDgcjnbDlYnD4XA42g1XJg6Hw+FoN1yZOBwOh6PdcGXicDgcjnbDlYnD4XA42g1XJg6Hw+FoN1yZOBwOh6PdcGXicDgcjnajKJXJ9u3bbceOHYGATIfD4WgtkB/IlJgcu6JolQn48ccfg+nKxOFwtAfqnLoiyY2iVSaQlIjsTk5OTu0ldVIdTVGUyoQC/+GHH2zdunX28ccf2yeffOLk5OTUJkKOiDZv3pySMo5MFIwykdZHCciuEYYIaJQBFFY9BYUB69evt8svv9ymTJliN998s91yyy1OTk5OLdKkSZOa0MSJE4MMge68805raGhIyxpkkOyZIxaeCSt5JbkGff/998GtmFAwyoQCEVFAY8eOtSuuuMJGjBhhX3/9dRN/Cun222+3v/3tbzZhwoRQMLhBFBRhGJEsWbIk8FZhOhwOR2shmYL5wAMPpO2SRZjffvutjRs3zi677DJbtGhR2j2m6dOn2/nnn2+vvfZaeC42FIwykTKAZs+ebTfddFPIcAoGhYG7CvCpp56yUaNGBaUzc+ZMq66uTvcWFIYh6T//+c+iLDSHw9F1QIZAyKAHH3wwmBpxQDyfdNJJNn78+CCTTj75ZNuwYUM6HmGYJaFjvHXrVjv66KNt27ZtKe7Fg4JRJhSOCuiOO+6wGTNmBPtbb71lZ555ZigwQOFUVlbac889F8KvWbPGzj777HShqtAZmbz66qvB3eFwONoKZAhyBXnDyAQgY2J5c8ghh4SRB8+DBw+2WbNmpeOxztKvXz97/vnnQ9iLLroozaeYUHDTXBTY+++/bz/72c/CfOVRRx0VND2FACgghpJMYWH/9NNP7ZRTTgnxAIVE+D/+8Y9BmcDTFYrD4WgrkB+iU089NcgXZA6QfGEGBZl19dVX23/913+F9RXJHWZJSkpK7OWXXw7PjFJuvfXWYC8mFNwCvKi2ttYeeuihMFV16aWXpgsGkymuxYsXBwXy3nvvhXlIFarCUYAoE4fD4WgvJFsefvjhtIzJBGshTz75pF111VVBuaiDXF9fb6WlpemRCWu9c+fOTcUqHhTcyISC+u6770IBfPXVV0HTP/vss1ZXVxeUyxdffGGvvPJK0O4oE3ZfMBrRkBMCrkwcDkdHoSVlwlQWMuudd94JoxfA+sjjjz8eZBMjFWZUPv/8czvxxBPTMy3FhIJbMyGTmboaPnx4WLB6+umnQ+GxBsKiPCZhnnjiidADuPfee5soElcmDoejo9GSMmFUgsxiGzEKA5mEgmFzEOGRS/PmzQsy7YMPPsjKY09HwSgTMl+kzBe0HhK7AZ7lB3hWIbkycXQYGmqtqrSH9eiRi/az8qr5tro+/52DDbVVVqr45TVWl3IP4PcGVFntzqrt2M1ArkC5lIk6tLIDwskO9F1cphwrFhSMMhHizJZyEAEVTqw4Yn/BlUn3QJOyx0g9B7fkL9QT6hOP2/m30x9S5yWED9EbzV0QFEqZVdXWJw/1Vlt1rJXXrEvs261+dY1VlPW0nkNqbH0r5ERQKJmKxFGQUB1pbs0ExPUIov5JngG5x0qmWFBwyqSj4Mqk+KHGqgb64dq1dtopp1j/kn72i5/93F5evDgJZPbvDRvt+D/8wUoT9wP2H2BPP/V0iLdg/nz7+c9+ZiV9+9pRRx5p6z9ZHxRPUDqZyKlMGrF9dbUN7DHIqldvs+11C21YolzCiKX6rST091a3aISVRaOZ0qpa25ZVmayzmvJS61GajEy2pUZEh5RZWc/S5PfetFXVQ6wnPHoOsepVW1JxHJ0N1bGWlEl3hisTxx6LeFSBcrh++HDr17fESvr0tb69etvRiYKYM/t+u+RvFwe3kt59gkI56Fe/tgcfeMAOO+RQ65OE69unj/UrKbFxY8bY9oakx5hNVrSgTKyuxsp74L/WFlUMtCE1H1nD+hobUjrMFm35InErC+HDaGRgta1OOqs5RybwQpk0pMKkwjemYajV1NWl+Tm6Bq5MWoYrE8ceDRq2pgyqJkwICgOFwujkzDP+bJ+t/9SmTZlqpYlbv0Sh4H7s0cfY+o/XhdEKYffuV2q99+pls+68y35MlMmOH7PMVeU9MlndOLJIj0Ia42xHsfTkWaOVViiTdBim1J63h6rKk9EJIxVXJl0FVyYtw5WJY48GDZtRCQrli88/twN+uX9acbzx+r/CKOO7b7fZrwccaHuXlAb3ZxYsJKI9M39BaiTTx359wIG27Ztv7Yfvvk9kdhZhkfeaycYwMpHCaARuFcmIoumKepNRR+Az1ybWrLbtuZTJlkVWUcr01vpdR0aOToUrk5bhysRRNECpcODe0qVLbXUyQpCSweT7JD6A5UhxKSDo7bffDt8t8R2T3HdBUCQaaWSjpru5dq6ZJH49meb6Mgj/neGPtcqqi3fu5krTAKtYVJse2ZRWVlll+N3UKKR+qVXBt+wyq0oUVs/yWbaqFTvIHG2HK5OW4crEUTRQI5cSiZ8Bz/E6C4RfbIo6FNs/spoLpqS3+m5fP9eum7UqGYs49hSoXrgyyQ1XJo6iQTalgQn0HCsN7IqDf2acDkP9KqtJRhKNo49kFDPxZatzTbJHQXXGlUluuDJxFBWkLIBMXUQk5YG7lAjgYzIUSBzX4YhBvYBcmeRGwSgTFVYmtcYPSCBw0yJz4bGfo7ihclaZx+UeP2eamcjl7ui+kFzhfEBMEcBU50T22B/Ebpl+xYKCUSZktogjUp555plwONqcOXN2uWmRxVQOd+SiGsyVK1cG97h3+dFHH4WRCc8Oh8PRViCPJFdQJsgZ3HjGXcRJwVOnTrXXX389HR4iPPcyIcsY2cAjPgaqWFCQyuT++++3v//97+FQx5qaGrvwwgubFBwjDvy50wSF8eGHHwZ3hcH0kYnD4egoIFdQCrppUR1XETctIpO4rG/QoEG2cOHCtOwhLHczcQ35Sy+9FGSWK5NORFww3Fg2ZcqUUAhs3aQQsKuHwF0munxGhYIdP4CJMqHgHA6Ho71Qh5SOLvJFSkI48MADg8zC/a9//Wt6vVYjGE48l8xijU6yqphQcMqEAvr3v/8dbkocOnRouBvg3XffTfthMuLgtjNGLNx3wj0CFBJ+jGbwf+yxx8L3Brjh53A4HG2BZAsmCgFFwTdLyCPcII6VR2Yhk7gag/Ai/DmantsZzz333DCFj3uxoeCUCRnPXSXnnXdeGDJSCCgMCk6FFx/lPHPmTJswYUJ4hrhQ65OP11ntsuVBqQCFhRRX7jE1Okbk2KOgMoYoz9hURyR2F/EcE24ORwzVjTvvvDPsFIVUVzC51x2ZtWzZMjvuuOPCrYq4A+oeF/7xvGXLFjviiCPss88+C37FhIJRJlIW0PXXXx/WSsj8TZs2hXvgv/nmmzDq2LZtW7oACfvoo49aVVVVsOMmAcGXzvGaCX4QleCpJ5605597zhpSw03iEsaxZ4OylAmp3FUHIE07KKzKnmfZIYdDUJ2gjmgBHrvqDDMpffv2DTKL+sUFWJdccknouHKyAuEUH7ejjz7aNmzYkOJePCjIkQk7H/bff/9QKCxsjRs3LigG7lFmiMn98MOGDQsLXlzir4IhfjCTYcWHH30U4lC4YV0lkQ+Pz33Mev/nXuGwP+jG8RMaRyDRWUzYRI49EEnBbVd5powff2SHIIqi8TnUh5SpeqdngIBwOGKojug7E9UR2VEkP//5z8MsCjIJJULn9+CDDw7h7rrrLquoqLATTjjBRo4cGdyKDQU5MqHgWHhn2++LL74YtDnDQxQJV2F++eWXYU3kqaeeCluAKVAJhsAref6YkUkSHr/g/0OD/fbQw2yffqXWj5NlE/p/++xrry+vDfdX8LvIGggujZwcexJQIiiNp56cb198viE8Q42XYpk999wL9so/l4S6orpG3WDNDSHBqFd1qAmanM2VOuyxfrUtDKf34jbQKubMsOsm1VpDOIq+8b6S4tuv0z1BnZAcyfzOBFKdQWY98sgjYVYEN86Jo+NLPWNNhWt7n2NGJKl/xCs2FNzIRAWjzNazTIA9LsRdzIQ+WrfOXlnSuKOCsBu/2GB99upl+5b2t5K9elv/PiXWN3keN3pMOHI8zRNK4jSkeDkKF5RXTJs3f2Uzps+0668faZMnT7X6rxvP7UWh/Otfb9gNN1TayITohKjTQmeksrLSRo0aZffcc0+6HuyC+NRgztoaMsDKKmpShztut/pVs2zoRBRIg9XVDHVlUmSgTlA3YmUi6DkmoLqUza8YUTDKpCNB8/74k3X2akqZJCVoPya9gbLf/DZcmsQR5SW9Gkcnc+6bnVYmgQibIkfhg8apsrt/9v2JYhhjN4wYaSNHVtrs2XNsxYo37V+vr7Axo8cmimRUym+kvfzyy4nfikTpTLYxY8aEKVXoX//6V+C1CyJlEu4uCacBZ+twxMpkS8bNiBwdX5aMZBJFVFa6693vjoKFFIEfp5IbRalMKOr4bK5QEZLe6dIlS8KFSdx5wW17D9w/x26beptde801tnHjxvS0B6bmzx2FC8oKwR/KN6HPP/88fBx2ww0j7cYbbwxTo6yXEOaf/3wluI9MaO7cuem477//fhiZoGCY1453+zVBWplsDsoiXKubqiLhzpEw3ZVQ+RxbLmUS4mTcjBjcGq/3dew5UB1zZZIbRalMQLaDHlESYMb0GbZwwYJgB9x9cfzxx9vWrVvTvVKvMIUPlRWmypadNWzYYBMHBzyqgwCxjZydf2zT1BobxGiEaa6W7zRBmWyxLYuGJaONpgph5yVW8cgky82IaQXjnZU9CapDrkxyoziVSVLWnyTKZEk0MkFAsNDKF6w33HCDjR07Nigc9URZPLv2mmvtgzVrwtWt27Nd3eooKKhcIexq5OyiUbnih0LBxJ1z3mIFA/HMN02x2y5IKxOtmexnPcun2NI6TiTe3qhgMpVJtpsRXZnskVC9cGWSG91iZELhI0yY0mA6Q9MaM2bMCIezvffee6G3yrcs9FyvvfbaIHgkiIiPCSS4gFeqboKgAFLTWFl3cyXUs9yqFq62+tRurhBu0cKMmxEn2oyKg1PTYb5esieBtg65MsmNbjPNRQVAITANcuutt4ZKQe+V7XvvvPOOzZ8/P3x5z9a91157LSgc5tClPKRY4mevVA5H9wBtHXJlkhvdamQCUCBr164N0x1AC+34QxxzwPctHNHyt7/9LRw6CeIKhB3FotGKw+EobtDmIVcmudEtlIkUiRSAKobcscfuAKXD9NeCBQvC+WCstSxfvjx8MAmkfBwOR/FDssGVSW50oTLZbts2fWQra2uttnalfbhpW9jCK6iwJKRVYHIX9AxpVCF/TAn4zGku8YzDgvj3Mv1juuOOO+yyyy4Lx9rzlStTYnyroLN3hDi+zGz2TMRhHA5HYUFttzllIjkSQ/JFMgL/+LmY0CXKZEf9KptXNcQO3LvMBpWXW3n5aXbsgWU2uOoJW12/84wbEaMEHZ/CxVcojXgrJ4Q/R8zr+xDcNLoAmcqkLdBvqQIwUrnmmmvCUS6kh1EKo5Wnn346uLGYz64gRjWKr7ikDegds1EcHtPhcBQG1EZzKRPaNyeWs82cKXS1YxH+uOMveVVs6Hxlsm21zZv+oC1evcG2NSmDBqv/eJk9etcTtjJRKCoshDTX8nKo45lnnmk//elPwygAcHYSBQEdc8wx4duQgw46qMl3AyrojlAm8IwrDnZ2fHHUNKMU0kEYgJ31Fo5bGD9+fFAuvAdxVHEIo3fEFAEUkMKJp8PhKAyoreZSJnyrts8++4QTgQ8//PDgFssj2jdH03OJ1qxZs7Ly2NPRycqkwTbWLrHVaS2SCNLNq23xvMds/pKPrB7nHz60Ja81Cl2IArjtttsCIVQpJG4uU+bjz84rjr7AjQ/RuGMAeyyEO2pkIlMVA4UAnnzyybC9mBGS/CH8OYySC71eeOGF8LU1V3jSI2EUJT4iIDf1aGI/h8Ox+6E2mUuZ0OmdNm1aaP/nn39++npfwtK+OeEcmcWH0UceeWToABcbOn1ksiMR8Ok9T9+8btOGXGDXTZhglVeca1c9sS69bqLCIuNXrVoVjmpGSfDNB4vg8oP4WhlBTWExrXTOOecEu4Qy6Ahlot9ESYl3nA6Ovmfa6/bbbw+VJA6n+BAVh+k60sOIhWkxjscnjYrDWgxfbvMtDM8Oh6NwoLacS5nQrrlp8d577w0zF3QoCYdcYvqLmRadGMxFWsxgFBs6WZnssG2rH7PJd71idQ1JAXy50CqH3WeLl9fa8uen2xUz3korGhUWRC+eKS4KRiYCVgqDazF18RXHPZ9xxhlpP74ZYWsvHyQivMWzs8Dv8l0KF3otWbIknQ6Z2X4bPxbuOWiQKTwq6MiRY2x05TgbP+7GcHw60Rrv4GhMv3jJnou3w+HoWMRtjtMzUASMPGL32bNn25///OfwDRvT759++mnwp61j79+/f7jqF7fLL788jGKKDV2wAL/DGjatsJrb77eX1n1pny6+w64c+he7JFp8B2hsCDB9RO+dQuJ8pbKyslAoApfzP/vss2EN5c033wwXZalgtfjN+sXixYuDHb/OArx1+2N5eXmoMAJpjtMtkM7Y5IrPEdePStHIRCktS/x2plnh9I5A7+lwODoftGPa35w5c4JMAsw44MbIo3fv3uFud2QYh4yeffbZTdp+r169wnQ3soJpezYPFRu6QJmk0PBve3veXXbXcx9mLMQ3gkKBKIxbbrklfDTI1+koi0GDBoXFbHoDmIw4WABHoHJKLAWs+BQgApfjUBgpYMe9sxALetZPOPNLdx7gJ/9swI93YFF/6tTb7frhN9iDDzycKKRXE2X5XKIMXw73beid9I4t8XU4HB2HuP2pbSOn1A6Z4mZhHSWCHWXBsUycBcjMA/GnTJkSrvJFfjGFD49iQxcokx9s8+qXbN6jC2zJx1/ZltVP2fTqZ+yDaFQCVDAQGp/1kiuvvDLcNcHaAsqBjwexE4YFcBa17rvvvnQ8FTAFtX79+vSwsjMLjt+TqUrHFBxfz6P85B9DbgpPujds2GjPP/eCfbeNk255H0Y834X1I3o8jLJYT0HB6p2y8XY4HB0L2pnaKlPoanuxQmHEgcziat5HH300uLFuUl1dHeISh9mW4cOHh1sX8S82dPqayTcrZtiQc6+1CVWj7IrBI+yJuh9sR/37tqD6blvwwZb0ArwKBaiw9JzpJ8p8hgiHqZGJ3DsT4q/fUnpRAmwW4HsUpUv+sjd5Tk1tyU3gmaE1mw24xpgpPtaGGNWIB6Sw8XPMx+FwtB5xm9LIRO0r9lNbi/1QJEB+MlFExYZOViY/2pfzb7Tra16y2tql9vy0UTZj5TeNXjvq7bPP6tPKpKPREbu52gpVIsxNmzaFLYGMqjhkEjeISiVTFS5fEJ73Q7GgsHhP3cUiXpj6jZgcDkfrofaTazeXoyumuRo+tVerr7ehgy+x0TVvN35b0gXYncpEAh1hTg+EZ76NOeWUU9LTVABT/vmAsMQhfFyh2dHGnCxbD2NkVnqeSRPkcDjyB20HcmWSG50+Mtm6eYs1P6D73r7anBqtdCB2lzJRpYvtEApg5cqVdvXVV4e1D7lr9JConoiyV1aFlSmlAqFo+FCSnWGMVti4wNRYHCcO73A48ofajSuT3Oj8NZM3nrCH3v4qh3j8wTbVzrVHV9annjsOu3NkguAWUfFik5EJOz1Gjx4d0rhzlNGyMiFcPsTv8B0LioXzwjiQksXAmIfD4cgfajeuTHKj86e57DurWzTZrqycYQ/MX2zLw6nBr9iix++2SVdWWNWiT1oYubQNu1OZtAQqI9sGb7755nBOD1/HD7uiwoaUD7ZR14+wf2/YSKBU6J0qpq1gPYXNCOxzZ4cb241Jg6bN1DgwpdykDHneqfAcju4JtRNXJrnRBcoEbLdtdbX26LQRdvHgcisffIlVVj9ptXXfFOUCfEtAOAOENQqFA+L69y2x3j/5T9u7X6mdf+55tiPxE8ij9igToAbA+WBsXeTSL0ZJ7AiT4oghJQK88Ti6O1yZtIwuUiZdj0JWJghuKiQm35GUlJQkyqSf9dmrl/Xr09f6l5bad9u2pUK3X5no92Ilxs4yvl1hYwAm25eVJoWBpFTk7nB0R9A2IFcmueHKZDdAlRFz2bJl1qdPn6BE+vbqbSWJCTGCEAjdnuorxcDvxSbTXIARyuuvvx6mwbifhaNo8EeJsEOMWyb5KMvh6K6gzUCuTHKjC5XJDmvYutW27fjR6j/50Oq2Ne3pqrAk7GICuGfzg3AH2IU9QZmQbgQ5R1KXJApFiuS3v/ltOCKGY1YUrqX3bQ6KJ7vMbHaOhHnjjTeCEnn88cfDwXbcz4JCUTpAtvh6Bpn+MuMwDseeAtXdXMoks42CzGeAXe232NBlymT7xw/bkP8qt7s/2GYNG2rtrusn2bN1O8/0p5esnjI94tiuL70FFQh+QPY4TCErE4E0k3YWxA856GDr3auXHX3UUVb/9dfhFNJDDz00HL2gdQ1AvmCP37UjIH7KW7YVcxQEpyFzzD5f8pMW5bPCKV16FxCnLdMePzscewpUd3MpE9ol7rQDCKg9YKoNK67kWzGhi5RJg9XVVNm0FZtSO7d+sHVzhtgvJ61IH0FPRkMUBN9jcK4V5+BgMhVEIahwOCyNQsUPevvtt9MFpcIqdGWi94kp87pPzhdjVHDPPfeEyqh4CqN37WjoN7iYDCVSWVkZ8pmdYBzlwqiF6TDuc6G8YgWntMXPkBDbHY49BarHuZQJ7sgrHU+PjFIboI0go/CDCOvKpM3YYT+svs+uGvOwLV6+1BbPu80uLjvMzpuX/XIsXSQFcYIwl0bhTqFg8t0EdwJwjDMCTvfEKz4o9AV4oHeGAO+HXSbEe3HvCcfsU0nZUqx86GgoHQA7v1FbWxsW6WOFgZ1jYrh3BuWib1n4GJMRjdIuEj/ZHY49Daq/uZQJh7sibzCPOOKIIH8IpzbD6eYcTIu84iI82nCxoQvXTL6zDbUP2OiLh1j50GE2+YlVTY5WIXMlRFUAgDtCUBa4IcQIQ6FxOifKhItn8FMcxSv0kYneVcRz5ntAPCcW2574U1E5dZS1jODeiYjTEKdF6c5MPyc9M12HUuEWTHaIoWx045x4Ohx7IlTPcykT3GgfXJR36aWXNmkrEGfzXXHFFcE/c9q+WNCFyqR5KNMhCUoUAhf0y11AqJ544ol2zDHHhG80NKQEKBAKjgu2EGzFBFVO3o2b2vTOKFkB/7gSK0xXQmXFGstdd90VbspEsbDZIBsUHsgem5n+me+kMLvjXR3Fj7gOMrpAvnBBn9zlh8m0MLsiqYtyB3xPhszi3hM2tRQjOl2Z7Ni22T6rqwvHezSh9S9ZzTN1qVA7C0wFgPbmyl6GhwhHCFBI2DEh7hDgUhoVHj1hlBBz+rocq1gQvzdTXoxS5s6dG/zkTh7IDnU1Mn9XZcKcMSMWpsQ47ZjvazRqiUnIdJef6gLP/I78VD8cjs6A6hubUpAvkOq56jydut///vdhKhooDqTRCLcyMg32+eefhzDFhE5WJjvsm9ob7eAePazHLlRq5TXrUuF2Cg8yHpOLZPbdd9/0qIPvHChATE134f7II4+klYmI+ITtisuxuhLKH0gCldEXO6445FHvGofZHVAZxGmBAG5MiXHSMQof5cK6C9+58H2LGl02Eh/sen/Zxdvh6GionkHxfSaZxNoiHTzJJuo5HWfVW+QW9ZsZFTavFBs6f5prxzp76sFa25p6TOPHtfbqsujDvIyCYReThosUDj3bU089NZgQNxlyDSbbVjN3QWFHWDEdhr1YoPfTO0qgsug9Y8aMcIAkO8BUmaF4CqwrQHogflvpUBnEZhwOky/yOemY0QvKhUVKdpPRy1M48eOdUJ708jL5OBwdDbUz6hgzArFbXP/o1FJn9UxHGDlFfaXTi7w6//zzQ/0uRhTkmomIApGfTIiCFBQGU3bAyEQ3LRYLMvNB0HvTC6JCM2+LMiUMfgqvOHE+dTTi38lmz/Yck/xQkChGjV4gRi+8F2XLuhHvShiVfRw/JtCcvyhXmNYgk4ejOKC6wMgkU5EIcdkLChPHkXuxYfcpkx1f2rr1u4xXOgwInELezdWZ4MpihtKYQKMTKjDD7D0FcQOkofL90WOPPRam9VCY3GDJRgTAexEmG+Cj6TOUFBBf/PQ7QDz0DLDn4h1DceAHYh6OPRuUJZRrN5djtyiTHdaweY29cvcwuyRaM+lodGdlguCjxz5mzJiwi0Tbp9UI8hGMuxtqvBDphST02XSBMoFmzpwZ7m1hUZ/tyJhsv2Sbsq4yFo/YhAQ9i39M+m3s+QDFrbD5xnEUPlQfXJnkRhcqE46hf8MWVF9px+59sA267CK77lFXJh0NKjpCEQGIYGPedurUqXbbbbelj5zfExqDGq+I9wG8G+sokydPDkfO8E646Z0hzhdbu3Zt+OCSr/VRMDHhvmbNmnBScsw38zf1u7K3BIUXOYoHqgOuTHKjC5TJD7Z59Yt2/4QhduDex9mFQ8+yEYs57vwb2/xV45RDZ6A7j0wyhRqCEuHJlcH05Fm4LnSowZJ+NWQRbmy6iN9R7nE4kM0dZcTaCycLMJph0V+KBuXDNzEspLLjRtOC4tccCANPKSZMR3FAdceVSW50sjLhGJW77dTSXjagfJq9uvF7a6ittkm1HX9Nbya6szLJhBoCQpXzg4499thwHApuEnhqIISR2d2aDO+M8mAjAzvL2LkzYcKEcKQPpw7gppOcG/M0WNNmXd1nNmrUaFu16t1kVIiS26nABOzKYyA77nFZZCMQh8804zCZ7rFik7/CZEOhK0LlQ5xO2eP37ygov1yZ5EaXTHPt2Lbeamuq7NzBV9v0qqvtZpSJj0y6DGpcMt97772wpZotipl+NEiI5tJdmgzvLQLh/VN5ArH2wkdmbEfmux7WaBjNvLT4ZXvxhZds+bJaW/XOuzZjxsygTCZPnpIo669sR6JM4nwVz9iUPfM3QRwGAgoDtD6jcJjwkT/2bKZ45YJ4EE5UaMhMGyZpVp7oXTsK+i1XJrnRpQvwO7Z9YSsXVduVgy+yCTPGWqWvmXQJ1NAkbNTY5s2bZ1dddVX6rhL5K0x3gt6XPFB+KZ8AZqYfIw/sW7d+Y2+/9bZNmnSrjRhxg40fNyFROC8E4nuZ+LwyiO+fmFLDnSk1TgPg6BkUFqcC8LFb/Pv6TbkB2UUKhzfUGL4x7JYtX4ffiuNgB9gzIbfMsIWEzHfQu4HOqL/wg1yZ5EaXKpM0GrbYx6/MsNGuTLoEsRAR0eAgwO4nttliEhb30FC7UZshTzLzKVu+xW4SWnL79NM6GzdufFAMIA6LXRQ/M93IJgm2cbNpgG9ptHGA76SkdFBCnOggZYSJIoKIR33ftGmzfbOVDQnJbzDFltAPPzTY3f+4x0beUGnLl78W0hWnSfaYgN5Nz4UGpU0jEb5HQhHzDHi3joR+z5VJbnSdMmlYby9OvsD+t/Q/7D8GnJ6MSt6yTQ2dVyiuTHZCDUEkISI/QG/45JNPDj3ooGRw7iZtRkpVUJ5kyycBP0hCF2CiHOQnt9gfkh+QGyRBiF1pygwPFJbdaCghOgFMvd133xy7s3qWVVXdZDfeONHuvXd2GC2hSEaNHG2jK8eGkVJ6mi6xszGDU7ljYls17aeQd/7F+cLuvdGjR6e/To/zv6PA70GuTHKji5TJj/bl/Ctsv8HT7MXVH1td3Qe2ouYWm/zSv1P+jfO/6mWoomDSqGRXJcnmFscBrkxaB/KNc8/Ycsuur9cTAXXrpMl2wP4D7Gf77WenJIoGwUU4yinOa0dhgOKAmN5idLJ58xZ7Z+W7yWhpglWOGmP/mHVPUBTcO8OIhp1njIQwIdw0JZdJKCDOy3v00UftySefDCMn3Bk5LViwIHxMyqGjhNGuOIgjkdi8wHEinF0FH/whnhVPCg5TduITTiOwOJ2Y77zzTmjnnEzNiQh8d/TMM8+ED1Opnx0J6jqUS5lIJqldxBT7xbKr2NBFymSHfbNiml147/s7O7tbF1vlzbWpmxd39ibIZIbtDPFRBgzp6T1RCHFBsLWTow1YFFUhqfCAK5PWQXlHPtIYr7qiwvr3KbG+vXpbvz59Aw0ePDj4A+W3o/BAsWiaC6WyZs0HNn36jGT02Shk43YSm7FfJgH5A8yWwgO1Tcw4PIjDx0R4Rl1sYWekJ+KZM9xQiBBygpEUOxT1ESt3HMXp7CgobbmUCXKKaUhM5A5TbvH78k7IJBSxDqstNnSyMvnO1tZcGy64Ki//k5UN+F8bFOzldsaxA+28eevTykWVDeIgR12BydEZ9DrkR8GgXE4//fTQCznnnHNC4eGOv+DKpHWIGzyoGj/B+vXqY6W9+9q+pf2tb+8+dtCvfx3yOR5BOgoHagMqF5mULVNWKts4XEzya46IB79Md9zkLsiu39Lvx7+djRf+ChvzlR8mbtipi0zRcioCoyzFIUxHQr+fS5kgq5hmg8rKysLoj3BKI2fLnXbaaSHcWWedlYpVXOhkZbLDvls03MqrF4dFxSa0/BWr/XDn2VyqQCoAzdeyMPzEE0+kQjVWFCrOP/7xj2BnSIyyIaziAlcmrYMUhDAz6cnuW1JqJXslI5NEofQv6Wf77rNPmNIAIa+j8I7CgdpR3B5UvvIDmeFE2ZDpLh4AO21RED+5x2HjcPHvKY4oMx7AXW7iw3sBTkLAT98BdTTgDTW3ZoI76zdc6Afidz388MODzALHH3+8bdy488T0YkGnT3M11M60imkPWE1NTVOaXdVka7AKC1KlQaFwYCHDQtwUjjsDtNWRoe7ZZ5+djqcwDIM1YnHkh7gBb9ywwcp+81srSUYk/fuVWmm/flY9c6ZNnz49rKlw3D0jRMIr71VuIiATxO6OjkeuvM1WFjFa8gf4ifQsM5s9E6obmcBN7TZGJs84bi4/8cn1W22FfgO+UiYi+avtzJkzJxxdpGeIqbk+ffqEHXi4X3bZZXb33XeHuMWELlAmU628YkwQPuMvHmTHX1wZ7FWjLraKHMqEDKfgLr/88nBYodwAPRGEGXOT2Fk74UZGwkOaIuN+j3HjxgU7Q08qgVP+xHBcpOG7nmkwmDSa3/3ud2EthfxWWEx4yI6paUv5OTntKUTnV3WZe9ypy5BkDoR8Qh5xNS/rPcgsgB/H8uy1115BZvHM1b8ca1Rs6HRlsv2TVbaqvrHH0OQole11tnLVzjOiMpUJuzj6Jb1hdhBJuYj4yI4dHIB1k2w3LRKPkUns5tQ6Ut5pvh23WKkrHI2E6Ui+qmfnDiNJhRUPQXycnPY0ou6iVOI2oPqNP1utUTb4x+0Df6a2GI1gR+HwbVGxodOVif3YYPqcpOm5XGT4zqEoBaBCIsOHDRtm9957b7owWGc57LDDwp56jrfgBrOLL77Yzj333KD5FU7xOYJdPQEVqlPriPLAVJ6KYn89Kwx5zq6aK6+8Mih9bdNUuDi+k9OeRNR3RiqSVbjFdZsZkzfeeCMdlqsfBg0aFPyZ6rrwwgvtvPPOs3vuuSeEKTZ0wTTXA1Zdy7cldfbJ/Ik2av6aYK/7cL5VP7brNFes0WOicAQKRyZ+cYFCQMoEyM3ROpBvjEpiUD5AeS47ILx6a2DWrFl28MEH21tvvRWeVbYOx56EuM4yMgGSN9kQuyO34rai52JsB12gTKqstEcP67ELlVq5X45VlFBDodFQDkxDXnvtteFWRHax4I8fDUukxlasDc2xZ4M6CTEy8fqZHZ2uTH58Y4E9XZflA53v3rB5z9SlHjoerkx2H9TwZGdEArFZgs0X1113XWiUzBujPKRAUCpxXIejUKB66cokNzp/zWQ3wZXJ7kHc0GRHSchEcTB1tmzZsnBXCAv3HJ2BslE4jVIcjkKBK5OW4crE0aFQo5M9U5EA+fPMR2Ycg8/XwYxc8HNl4ig0qF67MskNVyaODocaW2zG9lipiLjFkLUVdsSwi48de0BhMdWEFSf510gJgn/K7nB0NFTnXJnkhisTx24HjTMewXAiLEeKo1hmz54d7nvHXd+7fJMomjf+tcLWfrDWvt36TVqReBN3dBZcmbQMVyaO3Q4pg1ih8Iw7IxZOQaisrAzngvF88K8PCueFlST0m0MOtQ8TpbI9Fcfh6AxQtyBXJrnhysRREFBjFaFIACaL8+z8uvTSS23v/v0bj8RPFElpYu7bfx+78u9XeAN3dCpUL12Z5IYrE8duhxoqYFQSj0zkHsL8uN3+fPoZiSJpPBp/7779wqnGJ/z+D/bmijfsq807j+dxdDNQTUSdANVRVya5UTDKRIWFAJEwkXssXGL/zGfFAa5MigzUgx8a7PprrwsjEu5a2Sd1RP7FF15kj9Y8YjfdeGM4H+yGG24IW44x+VCS88I45oLLlVRnspHqFMDUF/vyE1Hf5IZdlMmD+LsTpEXH2cRtRGmUva3Qe4pHzBPSM2amH4if5RaHA5i4gdgv5sk5ftdcfbXNuvMu+2rT5tDpUPyOgn43lzLBLa4Dcsv1vLvrRmeg4JSJMp7MJuM5egWTggJxgaiByF9xgSuT4gJlC/1740YrT0Yn/fuWWEmv3nbOWUMaBUhSB6gHCkt9YMGeAz/5poXrZvmuhQ8muf+Gs98wOTCUq2W5Cpbb8RQXE34xTz2LuMlwO4IrMekR/4jySZ5x43l7Q2Od3V0gzXG69W6xva0Qb9ll6rf0GzJBpltsp73H+S4z2FP5K2q8RTJxT/L5hutHWD/qQtLB4M6dffrvbc89uyjEF6KobQb8oFzKRPKqvr4+dFoUHkq/R/RcjCg4ZQLIbO5/3n///a20tDT0NqlonEYLOHOLI53x69u3r918883BHXDrGnBlUlxoIvioJ5GAQbAA9fYUVo0Wd9UtCS38aPjz5s0L9eePf/yj9e7d2/7v//4v3DfBuWIc1Ec8lJLqp3gGe6IswtW4KI2E/aSEz68OOMCqxo1vTBtp3I1QPmCSXgk82YHep62AVzYoj4HyLX6O4+n8N7llhk2XM4o6ldcNySj100/W23/2/ImVlpRYn716hc4F10xz5XRQ6CkQnSfMtkJpbm6ai4v69t133yCTuAqDcHqXSZMmBXnVs2fP4F+MKBhlokynAPiQjdM2OSmYisb9APKjkqIkmMJAYUCZ9y0DVybFhVC+iRkEI3YEdUIIDfx+iAQlFNcXmbgB+ctPz3RE3nnnnXCPOCcejx07NmxPZsqMs8UwUTLz588Pu8q+qd8aBNyWzV/ZqSefHDYGcL0xPeWjBx5pG7/YEH5vd4F34nsd7poh/XTQpEz1zphthfIOiBcmJDe5K//lRxvnI1WIvOSyO/L96aefDgKbLeG33357UPQTb7rJrks6lCOT/L910mS77uprbOzoMTZi+PBweRv5zaiEtbS9E3PImYObaA6sna1MuKMemcVIGLveW+Ytt9wS6g/vi2wqRhTkNBcX83OGE1MTTz31VPqmRYhKiZLgKGdO8OTeZ9zUQMSLAluyZEmap2PPRhAIUfkGh4RUL1TOmZQOnzIzCRAfyC2TH8CNevjuu++GkTHKhnvyEWxDBp8VhFmfpFdcypQLAi5RLFdWXBnqKuGpi5gITuomp1pLsOj+l1wUp0+QPQ4nN6W/dvly22fvvUOaIHrtQ4cODQomfke1nUwibYzOSCeCnnfg6BtdFMVR6hMnTgwCn/bKtQOTJ08OHT3u9UCAav2KMOPHjw+3pGK/KVEQXK4GHy6a4o508of8olfP70owpwq/0QzUmD5GJyf96SQrSd6tX9LbZ6qLMrir+s7gL6SjhafWA17KL9Ib552IKVQ+ukVmUUcUDyI8+YTMYiSsabBiQ8EoEykEiMp6xhlnhGsuqZDcTEbm40fBsI6CH5fREI474nGHaKzEv+OOO4JSKsZCcxQGGtdHfrSnnngyEWK9ggJBoDWafeymqhtDHUQIM5qhXtKzRSA98sgjYb0GwUodR7hiImy5YRQ7Ahp/RkdM9WJHKOGH4JaQ5hlBRjw+9uR5UkInnnBCUGxsWGCjArvfmMrj+BqIONxGSvvC5Bm+xJeS0K2apBthr/fhumwUog7rBLFSiqfUMOWHCeTXVhBXH7Fyt/qf//zn8P7IhPbyzgZ4QqyzkRcoQH5D73Tqqafa6aefHqa6jjrqqKAc8SMOWJ4odtJ233332XHHHZee2ismFNzIhMxHUVCJeWY3SllZWVqRxESFZXjMYirPqqjEi+8zcTg6AygTeswN3/9gV181LCz+oky4L/+vfznH6r+uT9dpmUDPsR8EYjOOF5u53ATstI1JN99ie/crDcqNDQuliWLhLnJ6zgoTx4cy+WaGkVKIw2ACTJHCiGJ/xYHaCvEkfTE/yQCZHQHxx6RDIFnEs/yYEmW0yjOjFK6yVpoUVvaTTjopjL6KDQU3MgGsgQwZMiTY2fZ39tln20cffRR6Sgx9v/322xCWAkKR0MtTYaF80PqE1zSXw9EpSBSJFApzKMuWLrXRoypt6atLwrM2BsSQYBEJqr+yx4j9MkFdF684HvZPkw4V6wlSJtD111+fDpfJM+aBKX/M2C7IrjixAFf7jHkKxJNbzK81IB6KBOi3tEFHzx0FvQN8kTVA70o6sH/22Wf217/+Ndi5lpdwTGfpql6mFuHBlCGd42JEwS3AQ2Q6Q2sUBVfzrlmzxt5//32rqKgI9lWrVoWvoS+66CKbMmVKUCCqQCIKjZGJ+DkcHY3MOospd5mqj3GY2E0kt9g9k4codgeZ/mm/5O/91e/ZhHHj7aLzL7AH7p8TwtNW9Bsxf9kz25JI/pnxYr9cz81RW0A8fgPE6YlHKh0F+CnPGJlg6jnOS/zYCcjGAeJwVS9XWOPHWskll1wSphR1tW+xoWCUSUeDxUPfzeVwRCg++dVlQPhDuXZzOVyZOBwOR4twZdIyXJk4HA5HC3Bl0jJcmTgc3QQuAtsOVyYtw5WJw9FN4CKw7XBl0jJcmTgcDkcLcGXSMlyZOBwORwtwZdIyXJk4HA5HC3Bl0jJcmTgcDkcLcGXSMgpGmaiw+FpUZuaXuHLDhBQvPj8If+DKxOFwdBQkg5pTJpJXkkUyAaZkl8IVGwpGmXAkCkQmqyCAMj0+ZTMuJBWQzukRXJk4HI6OguRSLmUi+YMpmQQwkV3c3yIe+BcjCkaZkMGxYuDQNq5S5X4AzuVSIWDiz30HnCzMCag8464CBK5MHA5HR0GKoLmRCTKLo+e5buDrr78O8kjyCnD4LNdloFiKEQWnTKQUzjrrLJs6dWq4A+C1114LbgrDYY/cHcDNcZzUyenA+IuAKxOHw9FRaEmZIHc46Rx/LvTjZHPJLMLjhsziHpRzzjknK489HQW5ZsKpmlzWs2HDhnDyJm7yh7hP+bHHHgt2FI3uM4HEi1ODpUx4djgcjrZAcgfiNHPJk9jk0ivuNOEo+rhjjMnI5Be/+IU9/vjjwe3MM88MV5IXGwpOmZD5HOV8wgknhEtmGKFwpLOmsvDnSlBdfIXSOPnkk9PKhEtnKPDp06eHEYuGmA6Hw9EWIHeQLcgeriGuqakJMkru0CmnnBLuMRkzZowdeeSRYfYEd8JwBxOXktG5hQfH0HOzZrGh4Ka5IIaK9957byiILVu2hMIBUihcV7ps2TL77rvvgjLRpTT4Y1KI9BD8pkWHw9FeSGEA3bQoErg+HJlFOBQOCgNIhvXr1y9ceQy484SZlWJDwSgTFIGUAQvvM2fODAXDbWUoExUmJtdjcu8zdha8uCubQoOkcOgN0BPArrgOh8PRWiA/JEeY9cBEzmCKuFGRO/2xc5slF2EhyxTuj3/8Y5BZ8PnTn/5kdXV1Ke7Fg4JcM1GBXHvttXbaaaeF3RGsjfzmN78JJjsluGXxyiuvDItZrK1QcMQTD0Ys6gng5nA4HG2BZBPEAnosZ2Qif4YPHx5uhj3vvPNCJ5gdp4MGDQoKhbXfCy64IPhJqRQbCkaZdCSkTJjmUiXALSaHw+HIB8gLyRCNTOQmchSpMqGXsH79+rAAD1QRMDXsdDgcjnwhucG3bbE80YyIo0iVCYXMB0JLly4NhS03FboXvsPhyBeSHRCbg5ApuKFgXJnsRNFOc/HRImsmFPjKlSvDV6cqeC98h8PRGiAzUCCsmSBH2KG1evXqJp3U7o49XplQmDGp0N977z276qqrbNq0aen93bijXDAdDocjH0i2IEOQKRMnTgzTXXzl7rJkJ/Z4ZRKPNFSwbAvm2xN2eTEiURgqA4euKbzD4XC0BCkTTtrgWBSgzikUH0LbnVEUIxMpiy+++MJuvvnmJr0GlAkfCPGBoyoApsPhcOSDhQsX2uTJk23t2rVBdiBrmDrnezg9O4pkzYSegQpVvYUVK1aEM7z4KpX93vInLP4Oh8ORDyRXOFWDM7huu+02W7x4cXDDz5VJI4pmZILJh0IzZsyw6urqsB+cBXgpEQi74jgcDkc+eP3118P5gMx4zJ49Oy1vJFcgR5GMTKQc2GHBegnPHFegL+C16C4CMtuLmJ+UVVuhveztTZsqeEfxAW3lFcdrT3oUt73pyYaYZ3vLsCPyDMCjvZtF4jzjvdrzbuLVnvQA5Q2AV/zcHsTpgmdb+Wa+J+abb74ZLu4D+gLesSuKRpmIaDAUNkqFL+DjRqQwcWXDjOO3lcQzm18+pPgQ6c0WJh9SGtrDI6b2vFNMHZHXyh9RtjDtoY7gHfNoK584Xlt5iNqblkzqCD7wUH3o6HSJZ3v5Zms/8NQX8I5dURTTXHFhy2RkwhY+Ch/itE8+OILuueeecFgkbvQ0dKS0wraGZs2alY4vyhauJSIdTNFhbysPEfE5dI53zeafDylfOMCOdadsYfIleD3yyCNhioC8zxamJYrzlukGzjfKDNNW4lBR0qjf0O+0hch3zPbkPUQapkyZ0q66CfFepOXOO+/M6p8vkQb4UIZ33HFH1jCtIfhRjtSvbP6tJfIdnsqr9uQZ78d78r7w4bZX8hE/nhkxOnZF0Y1MpEzi3oNGJnJj+ouPGgmLn5RQW4gK1hGjAEZSCI/2poe48KAhaMtitnD5EI2G0R3H0mTzz4f0LqSJPI/PS2stsSMPwJPGnS1MW+iWW25JT49CIPbPl0gXwp93bU+dUBmeeuqpu0zRtoXgRT3N5pcvkSaIMiS/sGcLlw+RHqDbULOFaS0h5OErQd/W/Oe9eD/O9hOP+F1dkeRGUYxMMqGCz1bhcWNBjZFL7J8PFC6Ox53OVDrc5NcWkB56yPCM+bUFxCddSmNboHfk3hhuvozfOaZMyC02SQ+NkN0w3DCXmVfZ+GRCfIiD+eSTT6bdgXjlgzhtEL32T9d/atsTvjsSPvnyUvyYyHelEVPuCp8LsR924l944YVNeDQXH8ifOIoHH0zyK19e2fzFh3rKKIBnAXd4Z4PiieI0sMuSU8D13Boojvjp/SD9ppArbdlAPGYIqKtA76nfwfTvSrKjKEYm+UA9PFUKCDc954u4comn0J5eC3zg3dr0ZAPxRe1JE2mBgNImiH8m4jyF4vfBVP4p7/ScD+Kw4gmwQ615VxZUiUP6gnCA3fbkuSH5jTyzn7hxvmDq/UVKZ3Ppi/Mszh8Q89RzrjwjnAQddv024UUA9+bSo98iDKNB8YLw0whR7rnSgx+IfxfwHL9PnI5cvDKh+EoL8RQXP34rFvq5+BJW4fUMCB+nKxtPR1N0C2VCJaBiqEJh4oapSqLK1BwIQ/hYEGHCuzV8soH4MkVthdKi92sL9C6ZeaQ8zMUXd0jxRMSNTQki+beEOKzSgSm70pUPxEM8Q1oDJe78RmLmA/GQ0BFfTKA8UFrlnomYTzo9qbC48wwhyBQWygRxFF+UWVcVRjywZ4PCwCMzHunAHv+O8iBGHC+TMnmKB8/5IBcfCMAvdsOeDXFcpQFSfMXDzHRzNEW3UCYUvioUFeLDDz9MT3PJLR/EYTE3btxoy5cvt02bNrWKTzYQn63NzCPDR42itYAPcbkLf9WqVSnXtgFe8OFrX77hIV16T34jWxqVz5gKH+c17tu2bQvTG7jn+66Egb788ssmR+R8/vnn4XTo1pyTxG9C+pg1uCHIEiWy8Ysv7JOP1wW3lqD32bp16y5rcJjkHWfE6fcUPhO4SxjT0+YiJYXFhAdlAMQHyoTcCcNRQuQL5RaHf//99+3dd98Nz/DPlh79rkg7I5XvgAvq4E9aQUvKROmGF9PM4qUwpJN1CsoxH6Ak+QKdaVPqk34HfpQFHy3DS+7yywTpAmz/1cGNUibkIXxol83lu6MR3Waai0pQX18fzuy6/PLLg/n888/nrGTZoIpPzwwBMmrUqLCr6KijjgofSqrCtQU0gP33399++tOftqvC0kjPPPPM9MebbQXvevrpp9utt94a1nK4dpR5ZKUtV77hTj7gR4PnSuW999477UYZnHzyyYEnZcC1y9n4ZIIGPXbsWPuf//mf9CI+jb2ysjLsqPvDH/4QeOcDhE9FRYUddthhIb2BEkWyLhF0Bw44wEr69E2FbB68E4L5d7/7XbjjmzTB69lnn7XDDz88lIGun44pE7gRF8F4wgknhPrJM8Rd4qNHjw7HBA0YMCAoKP1OJkgPQNArX4455piwJkQc+HJ7KfWWclGZZAN+/Ablw2+zo+/4449PL0yzWQQ3ypJ05+Kjd8b/gw8+CLzIF25N1boewpurbEtKSkLZ5gN2WNH2qJ+///3vQ9mTNtoid7Djx51G8e9nSyNuV1xxRWgrxBsxYkQIz4L+kCFDQh5Svuz+VHjls6Mpuo0yoRK88MILttdeewXBRKM8//zzU76N/vkARRL3wqh47Eg55ZRTgj0f6LeolPDieeTIkeEr27KysnZVVoQXgkS9q7aCNCEQ1RgRRPSOcYdyvavcUSQIbQQXQlvTLShwGiyAH4vMuLcERjIoH8KzG09pUFwEAuWQDzjDjaN2Dj300HR6MSuTMrj26musf7/SNN/m0oYfgnrChAmhXgHyvby8PIx6AGEglXM2fkoD9ZHt7CgQQF2LFV5paaktWLAgKw8gPpS7wjByPumkk0Iv/dhjjw1h8DviiCNypgfIT/7EQxGwWw276ha7Bm+66aacfPTeQHEwiYNCx87ZVxyi2L9/f3v55ZdDmJYQp42yp05MnTo15J3eUch8jhGniXCHHHJIeL7sssvSO82oKyia+Dcdu6LbrJlQUdg/Tg8WO42LHo388qkkCitBjR0hyV303FmvitkSiKf48GSqgNEEQMDhlk96soFeFGcH0fCZTmgrH0ADv+6664IAQdBpKgnKlWe4Q4B3hOJ3YicQ35oQhlEUPedsfDKhMJdeemkQOOIHH8qDsmS6MR8ozm9/+9t0epk+GzJ4sD045wEr6d0nzR/iHTAzod9nmzIjE+yEZUT39NNPB8Wg3UpMX+GfjQ9pUToQYAhE+AAEGe984403BmXK1CogbCb0+7KjjIiLIJTilt+JJ54Y8itbegB8IPHEPOuss0InjGfiYTLSmT9/flY+xMFdpvgwimCUQ3vEnREAU1Z9+/ZNn1rREuBDvvGOlD3lRx1lGzv1f968eeH3QJyGTOBOOIhdi+Qxds7eooPIyOTII48MbUk8+F3Hrug2ygSi58IF/1QKiJ43yFXRskGVCZNKx9QLPKnM4tsS9FuEhQcNXpU17i23BUwV0MCZ/x04cGCb101I49VXX23jx48PCgXhw7y2GlKu/OJ9AEqW9yA8UxqEh5iW0IdfhGUklotXJjQ9hcAhrnhSBtOnT8+bj+LSC8VOOi+95BJ7bXmtPfzQw9anV6/gBolntjLBj/h8w/GTn/wk7cZ0FEeVk/dMuzASIr5+NxP6LYh3kzKByC/K4aKLLgpTYKw54J4NMR+IfEEg0llByKrXDnCPpy1jUDa4k1bZ6QDQYcIOkQamwIYOHRrs2fgA5ZHsCP9Lkrymo0LnhA8XEf5MSfXp0yfv0SW8mBqmM0LZ8xu807hx42zNmjX2l7/8JSh0womygXj4bd68OdRxTgYGzGKcffbZQYkfdNBBYfTUHB9HNxuZPPPMM/aLX/wiVGLmV88777x0Q8i3kqjRYDI1peEvz/nyUTjFoSfLsJrG/t///d+tEoyZYITz4osvhvj0RJn2agtQjho1QCiVuXPnBjsCQe6ZID+lcNRQNXWAO2XAqAk7wuDcc88NedAS4EM4ptuYV8dOOhBwlEO2tOSCyjxWJmeccYZV/P0KG/Snk8KaCZeqyQ/IjIE/hHJEiSs8wpL3gygDjU7wzwb8IMJrZIKd9zv44IMDT+joo48OgjdOVwzciIc/04vUTcVlNHDaaaeFcPgfd9xxOdODu9LEuhSCmbZCBwE/iO86EN7whX82XuIB4c/oDD6sTyhdlB2dKeoB03hMEeYDNiVQPxkVKb10NJQelB+dR/0ORJhM4M7iOyMlfZyLG++s76voGAxORq16d0d2dAtlospG7+OXv/xlmOemsXGUA6DC5IO4QjKSoHFTAelNIjDy5ZMJeIo0R95WkB4aJIL6gAMOCBsF2gLS8qtf/Sq8G7uueFd62ggUkCuNyiP5Y2dkIjujG561gYEywL0lKAzz41qkZZoEgcKuIoQwI4B8AT9GgYK2BT/84ENWWtIv5brzd7NB7xhPcxEeZYDApAwOPPDA0HkB+DXHj3rKu8UjCIQcIx/ekd9AiKNkskGCjikj1U3WTDTqZRMFC8kIYEY6udKi9wDXXHNN4EW6SAPvBPbbb7/Qe8edUXAuxLyYeqJuki7Ki/qkNDPias00F3xox3xUq7JHqVMfsPOuGuU0l+9MG5KvjGjg9dJLLwV3NijQcUGZstakURlwhZId3UKZUAlEVA562fRaaJT05FRJWgIVUhWJRsWcOEcvsJio3lZboQrPTpfmKn9LIB6NlqkRNYy2gnl2prggFlrbAtLD6AiT/MEkXUxz0MvWKKclEIa8ZwEawQMvBBllADHaYT4/HygdKCPZIexvvfVWswvKMQgP8bsIH+ykEWFG/UIQ696LOHwm8Fe9YsSMsFc4trGzoYJNC0y1kF+EzZY+vYPqJsQ0DetUuMOLug8/priaU0oQceiVU8fJX0jCHrt+g/TSjrKBNCld5BPhWQciv1CSgLh0MvDj/fMBcQkPH9JHufE+KJThw4eHnWb5gHUjvRv8MAEjHE0x0rZbM43dXdGt1kyoCAy11RilSPKtJMRRoyeueMrMl082KK4acluhd4upLSBea/MnG+Cjd1LaMMUz3zTq90mT4suUe76I06JyzOSZT5rieNgxIfGM04o9F1/FjXlgj92V3jh8JuSPX7bf1TN+4qc4MZR+hSOeeIj0LH/smVBYKS3CAoUXXyj+rXygOAAzMy2t4SNeMQ91csRP7pAjO7qVMqFC6Bm7KlC+FUR8VKn0LDfxawvitIhnWyAeSk9bQXwAD/FrC5Qe+MS8ZJd/PqCBK77ixM/55lmcJuxxuuSXDy8J5jhObBdfTFE2vooHCB//Pnb9jp5j/xixn+yxu56VrtgtBvEVBnv8nBmX52xpAXE64rAyY3/cgMyWoPiAODEfPeeDOA0Qz6pnMR/ZW8O7u6FbKBNAJaCiMH9NZVCPDcQVsyUonOLEFUvrCe2B0tlWKF3qDbYV4gPUS2sr4rSoQcpOOeQDxcFUHJ3LpDJQmJbAu2TGwYzd83lfhVEcTPHDL+anPMyWxthNYYiHXfVU79xcWeDOjjdMhSG8eEGKH4fJBtKgdGESNi4r+cEb0nMmYn/9psLq9+Unez4QX8WL86W5PMoEPEDm74s/UD0T8q2z3Q2uTBLgnm/lUzjFEQ/gyiQ74rSQX3GDzbdhKg6m4rgyaQrcXZk0n0eZgAfI/H3xB65M8kO3USYOh8Ph6Dy4MnE4HA5Hu+HKpNtgndWUl1qPHj2aUmmV1Saj9obaKhtQVWsdPoBvqLWqAY2/sXux3bYsGmY9e5RaeU1+pwLvinqrrSq3qtr8DpRsgo7Ih/pVVlMxpG2/3wSqC0Otpk4J4t2GWEXNqsTmcLQerky6DdbZ3InzbP32BqurGWqlQXFsttpJdxeAoO8qIDCPbYcyaR221y20YRVzrS713C5s/8hqhgzqOGFfV2PlTZRJgvq3rLq8zIbUfJSoXoejdXBl0u0QK5MUgmDpkbgtslerypIe62k2Numl9uyxnw2prrEZ5fslbscmPeLNSeDvrW7RCCtjVNNziFWv2tLII2C71ddOTPySeFVT7KHalY09YEY/25KeeWkSp+wCq4BfzwusZv33icB92SYG/j2sZ/ksW1W/LTd/evfwOKTMynomI4zquYnwi+JuXpr1NxqFJM8nWPlph6SUyRZbVc078jvlNnHpalva7LtvDPnWo0dZ48igPvmtsp7Wc0ilTXxohTXoN5SWz1akn3uUj7IJygcyvUnYKba07stEyfHbA+2yitMaf7uJQG/M14FDatKdgUa+lVYVRhikKZXX5UkYlFiSth4Jn/LqtxLlk6XM0spkbToeSm/7+hobMnCi1da7OnG0Dq5Muh2yKJPYLQjsgTZs0TrbzLRQ2QhbVLfeFlWUNQrhLYusohQhXW/ray6w0opFiVgWNA30pdXVvmqrEUgIrWgqrbQsEVRbVlr1wEOsYtHKhO/ApoKzWf4pHgOrbXUSIdgRgsTp2djL3vU31tnq6tOsrGqp1W9flbglArbmw0alR7hEefE7PXsOs0VfooyaefcwPYRiqQ+/w7Tg93Wv2/Ort+ROS0pI78yHZDRYdUIqPYw29rOevGPId3jXJekd1OhGvADydaANrF6VyqeNSZoOaXwOvzeg8T1nzbBFW75I52kDiqE0ea91C3fN06BMkvcqH5r8Jp2EFEIenWbVq7elHByO/ODKpNshH2WSKQyj6aHUKCb0jCH1tgM0MulpZRV3W21dMirIVCaBH0J5QMLvxbRwTqNZ/jEPsMVWL5qT9M7p5WemOdtv6D3WhvdVb7zxN5P4615t/t0jZaKRSY+yCpuVKIDtzaYl9RvhXZQu+KVGGYRJ53syMovTFhCnAaTWfwbOsKULx9rAsv1s4Iw5NmMYU2rwZ7SiPExGLTXVu+bpOt4ZZTKwUbGlODd5R4ejFXBl0u3QTmUSRg6Z01uZaJxC2g9+zSqT2tDDLhu20Oo0NGmB/04ejQK1ND29lZnmLL+xBQXQODIJwjhM+WxuVICMdr5v4d13EbSJ8lw1y8r3G2sL5zeXlgTpfGBUMSA1pcf01gmNI4xmlcm2MLraOTJJEBTgACsbUm2LHkrCH5KMRmbhD/+BqemtFLLlqRTo6peTPDkheafU6CSMTAa6MnG0Gq5MuhVSPeFUDzWtUIJgiXqu0KDyRPhhL7VB5YOsNLgzN//lzvn3hHaZjqkekVqvQHi9me4ll1ZWWWXgF9NQe3D5k+n5/dOGTLPnt0RrJgk14R8ELu7syEpNVYVRUKVVlCWKY9qURGjG/KHoN8KaSWrksH6dLZ1YnlozIa3rE8HOukXynPXdE/7lv2/0T5TCq6/OsmGp9Y3y6hX2WWZaEmG+ZXW1DcSt6j6rVj4kef79LutEW3b+dpriXWfxmomcEPqlQcE0hN9hqit1cVZ6zSThw/TdLnk6zaZr9FI6yMoHJfbU1KGvmTjaClcmDseegLC+UtZ0xNHR8N1cjnbAlYnDsaegw74zyQam8/w7E0fb4crE4XA4HO2GKxOHw+FwtBuuTBwOh8PRbrgycTgcDke74crE4XA4HO2GKxOHw+FwtBNm/x8/0pomoicabAAAAABJRU5ErkJggg==" />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p><p>IDegLira=Xultophy, IGlar=insulin glargine</p><p>&nbsp;</p><p><strong>Figure 4 Mean HbA<sub>1c</sub>&nbsp;(%) by treatment week in </strong><strong>patients with type 2 diabetes mellitus inadequately controlled on insulin glargine</strong><br />&nbsp;</p><p>The rate per patient year of exposure (percentage of patients) of severe hypoglycaemia was 0.00 (0&nbsp;patients out of 278) for Xultophy and 0.01 (1&nbsp;patient out of 279) for insulin glargine. The rate of nocturnal hypoglycaemic events was significantly lower with Xultophy compared to insulin glargine (estimated treatment ratio 0.17, p&lt;0.001).</p><p>&nbsp;</p><p>In a second trial, the transfer from basal insulin to Xultophy or insulin degludec was investigated in a 26-week randomised, double-blind trial in patients inadequately controlled on basal insulin (20-40 units) and metformin alone or in combination with sulfonylurea/glinides. Basal insulin and sulfonylurea/glinides were discontinued at randomisation. The maximum allowed dose was 50 dose steps for Xultophy and 50 units for insulin degludec. 48.7% of patients treated with Xultophy reached the HbA<sub>1c</sub> target of &lt;7% without confirmed hypoglycaemic episodes. This was a significantly higher proportion than observed with insulin degludec (15.6%, odds ratio 5.57, p&lt;0.0001). The key results of the trial are listed in Figure 5 and Table 5.</p><p>&nbsp;</p><p><img alt="" width="366" height="197" src="data:image/png;base64,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" /></p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p><br /><!--[if gte mso 9]><xml>
   <o:OLEObject Type="Embed" ProgID="Word.Document.12" ShapeID="_x0000_i1030"
    DrawAspect="Content" ObjectID="_1782814247">
   </o:OLEObject>
  </xml><![endif]--></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>IDegLira=Xultophy, IDeg=insulin degludec</p><p><strong>&nbsp;</strong></p><p><strong>Figure </strong><strong>5 Mean HbA<sub>1c</sub>&nbsp;(%) by treatment week in patients with type 2 diabetes mellitus inadequately controlled on basal insulin</strong></p><p>&nbsp;</p><p>The rate per patient year of exposure (percentage of patients) of severe hypoglycaemia was 0.01 (1&nbsp;patient out of 199) for Xultophy and 0.00 (0&nbsp;patients out of 199) for insulin degludec. The rate of nocturnal hypoglycaemic events was similar with Xultophy and insulin degludec treatment.</p><p>&nbsp;</p><p>Table 5 Results at 26-weeks &ndash; Transfer from basal insulin</p><table border="1" cellspacing="0" cellpadding="0" style="width:612px"><tbody><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Transfer from insulin glargine (100 units/mL)</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Transfer from basal insulin (NPH, insulin detemir, insulin glargine)</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Xultophy</strong></p></td><td style="vertical-align:top"><p><strong>Insulin glargine, no limitation to dose</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Xultophy</strong></p></td><td style="vertical-align:top"><p><strong>Insulin degludec, maximum 50&nbsp;units allowed</strong></p></td></tr><tr><td><p><strong>N</strong></p></td><td style="vertical-align:top"><p>278</p></td><td style="vertical-align:top"><p>279</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>199</p></td><td style="vertical-align:top"><p>199</p></td></tr><tr><td><p><strong>HbA<sub>1c</sub>&nbsp;(%)</strong></p><p>Baseline&rarr;End of trial</p><p>Mean change</p><p><em>Estimated difference</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8.4&rarr;6.6</p><p>-1.81</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8.2&rarr;7.1</p><p>-1.13</p><p><em>-0.59<sup>AB</sup>[-0.74; -0.45] </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8.7&rarr;6.9</p><p>-1.90</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8.8&rarr;8.0</p><p>-0.89</p><p><em>-1.05<sup>AB</sup>[-1.25; -0.84] </em></p></td></tr><tr><td><p><strong>Patients (%) achieving HbA<sub>1c</sub> &lt;7%</strong><br />All patients</p><p><em>Estimated odds ratio</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>71.6</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>47.0</p><p><em>3.45<sup>B</sup> [2.36; 5.05] </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>60.3</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>23.1</p><p><em>5.44<sup>B</sup> [3.42; 8.66] </em></p></td></tr><tr><td><p><strong>Patients (%) achieving HbA<sub>1c</sub> </strong><strong>&pound;</strong><strong>6.5%</strong><br />All patients</p><p><em>Estimated odds ratio</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>55.4</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><br />30.8</p><p><em>3.29<sup>B</sup> [2.27; 4.75] </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>45.2</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><br />13.1</p><p><em>5.66<sup>B</sup> [3.37; 9.51] </em></p></td></tr><tr><td><p><strong>Rate of confirmed hypoglycaemia* per patient year of exposure (percentage of patients)</strong></p><p><em>Estimated ratio</em></p></td><td><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>2.23 (28.4%)</p><p>&nbsp;</p></td><td><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>5.05 (49.1%)</p><p><em>0.43<sup>AB</sup> [0.30; 0.61] </em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>1.53 (24.1%)</p><p>&nbsp;</p></td><td><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>2.63 (24.6%)</p><p><em>0.66 [0.39; 1.13] </em></p></td></tr><tr><td><p><strong>Body Weight (kg)</strong></p><p>Baseline&rarr;End of trial<br />Mean change</p><p><em>Estimated difference</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>88.3&rarr;86.9</p><p>-1.4</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>87.3&rarr;89.1</p><p>1.8</p><p><em>-3.20<sup>AB</sup> [-3.77; -2.64]</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>95.4&rarr;92.7</p><p>-2.7</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>93.5&rarr;93.5</p><p>0.0</p><p><em>-2.51<sup>B</sup> [-3.21; -1.82]</em></p></td></tr><tr><td><p><strong>FPG (mmol/L)</strong></p><p>Baseline&rarr;End of trial</p><p>Mean change</p><p><em>Estimated difference</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8.9&rarr;6.1</p><p>-2.83</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8.9&rarr;6.1</p><p>-2.77</p><p><em>-0.01 [-0.35; 0.33]</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>9.7&rarr;6.2</p><p>-3.46</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>9.6&rarr;7.0</p><p>-2.58</p><p><em>-0.73<sup>C</sup> [-1.19; -0.27]</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Dose End of trial</strong></p><p>Insulin (units)<br />Liraglutide (mg)</p><p><em>Estimated difference, basal insulin dose</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>41</p><p>1.5</p><p>&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p><p>66<em><sup>D</sup></em></p><p>-</p><p><em>-25.47<sup>B</sup> [-28.90; -22.05]</em></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p><p>45</p><p>1.7</p><p>&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p><p>45</p><p>-</p><p><em>-0.02 [-1.88; 1.84]</em></p><p>&nbsp;</p></td></tr></tbody></table><p>Baseline, End of trial and change values are observed Last observation carried forward. The 95% confidence interval is stated in &lsquo;[]&rsquo;</p><p>*Confirmed hypoglycaemia defined as severe hypoglycaemia (episode requiring assistance of another person) and/or minor hypoglycaemia (plasma glucose &lt;3.1&nbsp;mmol/L irrespective of symptoms)</p><p><sup>A</sup> Endpoints with confirmed superiority of Xultophy vs comparator</p><p><sup>B</sup> p&lt;0.0001</p><p><sup>C</sup> p&lt;0.05</p><p><sup>D</sup> The average pre-trial dose of insulin glargine was 32&nbsp;units</p><p>&nbsp;</p><p>Treatment with Xultophy compared to a basal-bolus insulin regimen consisting of basal insulin (insulin glargine 100&nbsp;units/mL) in combination with bolus insulin (insulin aspart) studied in a 26-week trial in patients with type 2 diabetes mellitus inadequately controlled on insulin glargine and metformin demonstrated a similar reduction of HbA<sub>1c</sub> in the two groups (mean value from 8.2% to 6.7% in both groups). In both groups 66%&ndash;67% achieved HbA<sub>1c</sub> &lt;&nbsp;7%. Compared to baseline, there was a mean reduction in body weight of 0.9&nbsp;kg for Xultophy and a mean increase of 2.6&nbsp;kg for patients treated with a basal-bolus regimen and the estimated treatment difference was -3.57&nbsp;kg [95% CI: -4.19; -2.95]. The percentage of patients experiencing severe or blood-glucose confirmed symptomatic hypoglycaemia was 19.8% in the Xultophy group and 52.6% in the basal-bolus insulin group, and the estimated rate ratio was 0.11 [95% CI: 0.08-0.17]. The total daily insulin dose at end of trial was 40&nbsp;units for patients treated with Xultophy and 84&nbsp;units (52&nbsp;units of basal insulin and 32&nbsp;units of bolus insulin) for patients treated with a basal-bolus insulin regimen.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiovascular Safety</p><p>&nbsp;</p><p>No cardiovascular outcomes trials have been performed with Xultophy.</p><p>&nbsp;</p><p><u>Liraglutide (Victoza)</u></p><p>The Liraglutide Effect and Action in Diabetes Evaluation of Cardiovascular Outcome Results (LEADER) trial, was a multicentre, placebo-controlled, double-blind clinical trial. 9,340 patients were randomly allocated to either liraglutide (4,668) or placebo (4,672), both in addition to standards of care for HbA<sub>1c</sub> and cardiovascular (CV) risk factors. Primary outcome or vital status at end of trial was available for 99.7% and 99.6% of participants randomised to liraglutide and placebo, respectively. The duration of observation was minimum 3.5&nbsp;years and up to a maximum of 5&nbsp;years. The study population included patients &ge;65&nbsp;years (n=4,329) and &ge;75&nbsp;years (n=836) and patients with mild (n=3,907), moderate (n=1,934) or severe (n=224) renal impairment. The mean age was 64&nbsp;years and the mean BMI was 32.5&nbsp;kg/m&sup2;. The mean duration of diabetes was 12.8&nbsp;years.</p><p>&nbsp;</p><p>The primary endpoint was the time from randomisation to first occurrence of any major adverse cardiovascular events (MACE): CV death, non-fatal myocardial infarction or non-fatal stroke. Liraglutide was superior in preventing MACE vs placebo (Figure 6).</p><p>&nbsp;</p><p><strong>&nbsp;</strong><img alt="" width="614" height="456" src="data:image/png;base64,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" /></p><p><br /><!--[if gte mso 9]><xml>
 <o:OLEObject Type="Embed" ProgID="Word.Document.12" ShapeID="_x0000_i1031"
  DrawAspect="Content" ObjectID="_1782814248">
 </o:OLEObject>
</xml><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Figure 6 Forest plot of analyses of individual cardiovascular event types </strong><strong>&ndash; FAS population</strong></p><p>&nbsp;</p><p>A reduction in HbA<sub>1c</sub> from baseline to month 36 was observed with liraglutide vs placebo, in addition to standard of care (-1.16% vs -0.77%; estimated treatment difference [ETD] -0.40% [-0.45; -0.34]).</p><p>&nbsp;</p><p><u>Insulin degludec (Tresiba)</u></p><p>DEVOTE was a randomised, double-blind, and event-driven clinical trial with a median duration of 2 years comparing the cardiovascular safety of insulin degludec versus insulin glargine (100&nbsp;units/mL) in 7,637 patients with type 2 diabetes mellitus at high risk of cardiovascular events.</p><p>The primary analysis was time from randomisation to first occurrence of a 3-component major adverse cardiovascular event (MACE) defined as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. The trial was designed as a non-inferiority trial to exclude a pre-specified risk margin of 1.3 for the hazard ratio (HR) of MACE comparing insulin degludec to insulin glargine. The cardiovascular safety of insulin degludec as compared to insulin glargine was confirmed (HR 0.91 [0.78; 1.06]) (Figure 7).</p><p>&nbsp;</p><p>At baseline, HbA<sub>1c </sub>was 8.4% in both treatment groups and after 2 years HbA<sub>1c</sub> was 7.5% both with insulin degludec and insulin glargine.</p><p>&nbsp;</p><p><img alt="" width="579" height="222" src="data:image/png;base64,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" /><br /><!--[if gte mso 9]><xml>
 <o:OLEObject Type="Embed" ProgID="Word.Document.12" ShapeID="_x0000_i1032"
  DrawAspect="Content" ObjectID="_1782814249">
  <o:WordFieldCodes>\s</o:WordFieldCodes>
 </o:OLEObject>
</xml><![endif]--></p><p>N: Number of subjects with a first EAC confirmed event during trial. %: Percentage of subjects with a first EAC confirmed event relative to the number of randomised subjects. EAC: Event adjudication committee. CV: Cardiovascular. MI: Myocardial infarction. CI: 95% confidence interval.</p><p><strong>&nbsp;</strong></p><p><strong>Figure 7 Forest plot of analysis of the composite 3-point MACE and individual cardiovascular endpoints in DEVOTE</strong></p><p><em>&nbsp;</em></p><p><em>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>Insulin secretion/beta-cell function</p><p>Xultophy improves beta-cell function compared to insulin degludec as measured by the homeostasis model assessment for beta-cell function (HOMA-&beta;). Improved insulin secretion compared to insulin degludec in response to a standardised meal test was demonstrated in 260&nbsp;patients with type 2 diabetes after 52&nbsp;weeks of treatment. No data is available beyond 52&nbsp;weeks of treatment.</p><p>&nbsp;</p><p><em>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>Blood pressure</p><p>In patients inadequately controlled on metformin alone or in combination with pioglitazone, Xultophy reduced mean systolic blood pressure by 1.8&nbsp;mmHg compared to a reduction of 0.7&nbsp;mmHg with insulin degludec and 2.7&nbsp;mmHg with liraglutide. In patients inadequately controlled on sulfonylurea alone or in combination with metformin, the reduction was 3.5&nbsp;mmHg with Xultophy and 3.2&nbsp;mmHg with placebo. The differences were not statistically significant. In three trials with patients inadequately controlled on basal insulin, systolic blood pressure was reduced by 5.4&nbsp;mmHg with Xultophy and 1.7&nbsp;mmHg with insulin degludec, with a statistically significant estimated treatment difference of -3.71&nbsp;mmHg (p=0.0028), reduced by 3.7&nbsp;mmHg with Xultophy vs 0.2&nbsp;mmHg with insulin glargine, with a statistically significant estimated treatment difference of -3.57&nbsp;mmHg (p&lt;0.001) and reduced by 4.5&nbsp;mmHg with Xultophy vs 1.16&nbsp;mmHg with insulin glargine U100 plus insulin aspart, with a statistically significant estimated treatment difference of -3.70&nbsp;mmHg (p=0.0003).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Xultophy in all subsets of the paediatric population for treatment of type 2 diabetes mellitus (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overall, the pharmacokinetics of insulin degludec and liraglutide were not affected in a clinically relevant manner when administered as Xultophy compared with independent injections of insulin degludec and liraglutide.</p><p>&nbsp;</p><p>The following reflects the pharmacokinetic properties of Xultophy unless stated that the presented data is from administration of insulin degludec or liraglutide alone.</p><p>&nbsp;</p><p><u>Absorption</u></p><p><u>&nbsp;</u></p><p>The overall exposure of insulin degludec was equivalent following administration of Xultophy versus insulin degludec alone while the C<sub>max</sub> was higher by 12%. The overall exposure of liraglutide was equivalent following administration of Xultophy versus liraglutide alone while C<sub>max</sub> was lower by 23%. The differences are considered of no clinical relevance since Xultophy is initiated and titrated according to the individual patient&rsquo;s blood glucose targets.</p><p>&nbsp;</p><p>Insulin degludec and liraglutide exposure increased proportionally with the Xultophy dose within the full dose range based on a population pharmacokinetic analysis.</p><p>&nbsp;</p><p>The pharmacokinetic profile of Xultophy is consistent with once-daily dosing and steady-state concentration of insulin degludec and liraglutide is reached after 2&ndash;3&nbsp;days of daily administration.</p><p>&nbsp;</p><p><u>Distribution</u></p><p><u>&nbsp;</u></p><p>Insulin degludec and liraglutide are extensively bound to plasma proteins (&gt;99% and &gt;98%, respectively).</p><p><u>&nbsp;</u></p><p><u>Biotransformation</u></p><p><em>&nbsp;</em></p><p><em>Insulin degludec</em></p><p>Degradation of insulin degludec is similar to that of human insulin; all metabolites formed are<em> </em>inactive.</p><p><em>&nbsp;</em></p><p><em>Liraglutide</em></p><p>During 24&nbsp;hours following administration of a single radiolabelled [<sup>3</sup>H]-liraglutide dose to healthy subjects, the major component in plasma was intact liraglutide. Two minor plasma metabolites were detected (&le;9% and &le;5% of total plasma radioactivity exposure). Liraglutide is metabolised in a similar manner to large proteins without a specific organ having been identified as major route of elimination.</p><p><em>&nbsp;</em></p><p><u>Elimination</u></p><p><u>&nbsp;</u></p><p>The half-life of insulin degludec is approximately 25&nbsp;hours and the half-life of liraglutide is approximately 13&nbsp;hours.</p><p><em><u>&nbsp;</u></em></p><p><u>Special populations</u></p><p><em>&nbsp;</em></p><p><em><u>Elderly patients</u></em></p><p>Age had no clinically relevant effect on the pharmacokinetics of Xultophy based on results from a population pharmacokinetic analysis including adult patients up to 83&nbsp;years treated with Xultophy.</p><p>&nbsp;</p><p><em><u>Gender</u></em></p><p>Gender had no clinically relevant effect on the pharmacokinetics of Xultophy based on results from a population pharmacokinetic analysis.</p><p>&nbsp;</p><p><em><u>Ethnic origin </u></em></p><p>Ethnic origin had no clinically relevant effect on the pharmacokinetics of Xultophy based on results from a population pharmacokinetic analysis including White, Black, Indian, Asian and Hispanic groups.</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p><em>Insulin degludec</em></p><p>There is no difference in the pharmacokinetics of insulin degludec between healthy subjects and patients with renal impairment.</p><p><u>&nbsp;</u></p><p><em>Liraglutide</em></p><p>Liraglutide exposure was reduced in patients with renal impairment compared to individuals with normal renal function. Liraglutide exposure was lowered by 33%, 14%, 27% and 26%, in patients with mild (creatinine clearance, CrCl 50&ndash;80&nbsp;mL/min), moderate (CrCl 30&ndash;50&nbsp;mL/min), and severe (CrCl &lt;30&nbsp;mL/min) renal impairment and in end-stage renal disease requiring dialysis, respectively.</p><p>Similarly, in a 26-week clinical trial, patients with type 2 diabetes and moderate renal impairment (CrCl 30&ndash;59&nbsp;mL/min) had 26% lower liraglutide exposure when compared with a separate trial including patients with type 2 diabetes with normal renal function or mild renal impairment.</p><p><em><u>&nbsp;</u></em></p><p><em><u>Hepatic impairment</u></em></p><p><em>Insulin degludec</em></p><p>There is no difference in the pharmacokinetics of insulin degludec between healthy subjects and patients with hepatic impairment.</p><p><em>&nbsp;</em></p><p><em>Liraglutide</em></p><p>The pharmacokinetics of liraglutide was evaluated in patients with varying degrees of hepatic impairment in a single-dose trial. Liraglutide exposure was decreased by 13&ndash;23% in patients with mild to moderate hepatic impairment compared to healthy subjects. Exposure was significantly lower (44%) in patients with severe hepatic impairment (Child Pugh score &gt;9).</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>No studies have been performed with Xultophy in children and adolescents below 18&nbsp;years of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The non-clinical development programme for insulin degludec/liraglutide included pivotal combination toxicity studies of up to 90&nbsp;days duration in a single relevant species (Wistar rats) to support the clinical development programme. Local tolerance was assessed in rabbits and pigs.</p><p>&nbsp;</p><p>Non-clinical safety data revealed no safety concern for humans based on repeated dose toxicity studies.</p><p>&nbsp;</p><p>The local tissue reactions in the two studies in rabbits and pigs, respectively, were limited to mild inflammatory reactions.</p><p>&nbsp;</p><p>No studies have been conducted with the insulin degludec/liraglutide combination to evaluate carcinogenesis, mutagenesis or impairment of fertility. The following data are based upon studies with insulin degludec and liraglutide individually.</p><p><em>&nbsp;</em></p><p><em>Insulin degludec</em></p><p>Non-clinical data reveal no safety concern for humans based on studies of safety pharmacology, repeated dose toxicity, carcinogenic potential, and toxicity to reproduction.</p><p>The ratio of mitogenic relative to metabolic potency for insulin degludec is unchanged compared to human insulin.</p><p><em>&nbsp;</em></p><p><em>Liraglutide</em></p><p>Non-clinical data reveal no special hazards for human based on conventional studies of safety pharmacology, repeat-dose toxicity, or genotoxicity. Non-lethal thyroid C-cell tumours were seen in 2‑year carcinogenicity studies in rats and mice. In rats, a no observed adverse effect level (NOAEL) was not observed. These tumours were not seen in monkeys treated for 20&nbsp;months. These findings in rodents are caused by a non-genotoxic, specific GLP-1 receptor-mediated mechanism to which rodents are particularly sensitive. The relevance for humans is likely to be low but cannot be completely excluded. No other treatment-related tumours have been found.</p><p>&nbsp;</p><p>Animal studies did not indicate direct harmful effects with respect to fertility but slightly increased early embryonic deaths at the highest dose. Dosing with liraglutide during mid-gestation caused a reduction in maternal weight and foetal growth with equivocal effects on ribs in rats and skeletal variation in the rabbit. Neonatal growth was reduced in rats while exposed to liraglutide, and persisted in the post-weaning period in the high dose group. It is unknown whether the reduced pup growth is caused by reduced pup milk intake due to a direct GLP-1 effect or reduced maternal milk production due to decreased caloric intake.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>Glycerol</p><p>Phenol</p><p>Zinc acetate</p><p>Hydrochloric acid (for pH adjustment)</p><p>Sodium hydroxide (for pH adjustment)</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Substances added to Xultophy may cause degradation of the active substances.</p><p>&nbsp;</p><p>Xultophy must not be added to infusion fluids.</p><p>&nbsp;</p><p>This medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.

After first opening, the medicinal product can be stored for 21 days at a maximum temperature of 30°C. The medicinal product should be discarded 21 days after first opening.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before first opening: Store in a refrigerator (2&deg;C &ndash; 8&deg;C). Keep away from the freezing element. Do not freeze. Keep the cap on the pre-filled pen in order to protect from light.</p><p>&nbsp;</p><p>After first opening: Store at a maximum of 30&deg;C or store in a refrigerator (2&deg;C &ndash; 8&deg;C). Do not freeze. Keep the cap on the pre-filled pen in order to protect from light.</p><p>&nbsp;</p><p>For storage conditions after first opening of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>3&nbsp;mL solution in a cartridge (type 1 glass) with a plunger (halobutyl) and a stopper (halobutyl/polyisoprene) contained in a pre-filled multidose disposable pen made of polypropylene, polycarbonate and acrylonitrile butadiene styrene.</p><p>&nbsp;</p><p>Pack sizes of 1, 3, 5 and multipack containing 10 (2&nbsp;packs of 5) pre-filled pens.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pre-filled pen is designed to be used with NovoTwist or NovoFine injection needles up to a length of 8&nbsp;mm and as thin as 32G.</p><p>&nbsp;</p><p>The pre-filled pen is for use by one person only.</p><p>&nbsp;</p><p>Xultophy must not be used if the solution does not appear clear and colourless.</p><p>&nbsp;</p><p>Xultophy which has been frozen must not be used.</p><p>&nbsp;</p><p>A new needle must always be attached before each use. Needles must not be re-used. The patient should discard the needle after each injection.</p><p>&nbsp;</p><p>In the event of blocked needles, patients must follow the instructions described in the instructions for use accompanying the package leaflet.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p><em>&nbsp;</em></p><p>For detailed instructions for use, see the package leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd
Denmark


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sep-2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>